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The aim of this study was to explore whole nation data, reveal trends and obtain 
updated numbers on kidney cancer (KC) treatment in the six-year period from 2008-
2013. The field of KC management has undergone substantial changes over the last 
few decades regarding surgical approaches, the use of pretreatment biopsies, 
surveillance and management of metastatic disease. We wanted to evaluate patient 
outcomes, and to see if new guidelines were implemented. 
Material and methods: 
Data on 4,449 patients diagnosed with KC (ICD10 code 64) was extracted from the 
Cancer Registry of Norway for all three articles. In Paper I, an analysis is performed 
on patients with data on biopsies (n=4,051). For Paper II, the data subset constitutes 
all patients with a surgically treated localized kidney cancer ≤7cm (n=2,420). Paper 
III includes all surgically treated Norwegian patients (n=3,273), both with localized 
and advanced disease, operated on in hospitals performing more than 4 KC 
surgeries/year. 
Results: 
Paper I: A renal mass biopsy (RMB) was performed in 20.2% of all patients. From 
the first to the second half of the study period, the use of RMB increased from 9.1 to 
11.5 % for localized disease, and was doubled among patients for observation. 
Predictors of RMB were older patients, tumor < 4 cm, multiple tumors and second 
primary cancer. Fewer patients with metastatic disease were without histopathology 
verification in the second period. Those without RMB had poorer survival. The 
majority of biopsies were performed in patients who had a cytoreductive 
nephrectomy (CN), and CN was performed in 35% of all patients. 
Paper II: There was a 28% increase in surgically treated patients, with tumors ≤ 7 
cm and the rates of partial nephrectomy (PN) increased, while the rate of radical 
nephrectomy (RN) decreased. PN was performed for 58% of tumors ≤ 4cm and for 
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14% of tumors 4.1-7cm. There was also an increase for minimally invasive (MIM) 
approaches. The regional differences in the distribution of PN and RN were less 
pronounced at the end of the study period. Furthermore, our results indicate a 
possible survival benefit for a patient undergoing PN vs. RN. 
Paper III: RN was performed in 69% of the patients and PN in 31%. Overall, the 30-
day mortality (TDM) was 0.89%, whereas the rate for localized and metastatic 
disease was 0.73% and 2.6%, respectively. TDM was higher in older patients and 
lower for PN and MIM procedures. The odds ratio for TDM in a low-volume- 
compared to a high-volume hospital was 3.35 and 4.98 for patients with localized and 
metastatic disease, respectively 
Conclusion: 
These studies demonstrate that trends in KC diagnostics and treatment are in line with 
international recommendations, and that Norwegian urologists seem to adapt to 
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1. Introduction 
1.1 Historical considerations for Renal Surgery  
Renal Cell Carcinoma (RCC) constitutes approximately 90% of Kidney Cancer (KC), 
and originates from mature renal tubular structures. In 1883, Grawitz published a 
yellowish tumor that probably arose from intrarenal adrenal remnants [1], further 
supported by Birch-Hirschfeld in 1894, which was named hypernephroma [2]. Its 
origins were discussed by surgeons, pathologists and radiologists from the early 
1900s [3, 4], until Oberling documented the renal origin of the tumor in 1960 using 
an electron microscope [5]. The “Heidelberg classification of renal tumors”, a 
consensus presented in 1997, still applies, but is regularly updated with new genetic 
knowledge and histopathology [6].  
In 1869, Simon cured a woman with a persistent ureteral fistula doing the first 
planned nephrectomy [7]. Eight years later, Langenbuch did the first nephrectomy for 
neoplastic disease [8]. Renal surgery expanded steadily in subsequent years. 
Furthermore the interest in organ-preserving and reconstructive surgery was 
highlighted in 1879 by Harrison’s tumor-decapsulation and Czerny’s partial kidney 
resection of a tumor in 1887 [7-9].  
After Robson’s work in the 1960s, open radical nephrectomy (ORN) became the 
standard treatment for localized KC [10]. The key surgical steps described by Robson 
still serve as basic principles for urologic surgeons today, and he was also the first to 
correlate the survival to tumor stage (known as the Robson staging system).  
At this time, a partial nephrectomy (PN) was only done for imperative reasons by 
very few urologists. When Wickham presented a 5-year survival of 72% in a review 
in 1975, the scene opened for elective PN. However, the topic was discussed during 
the next decades. In 1993, Licht and Novick presented patients followed for three 
years with a normal contralateral kidney demonstrating 95% survival and rare local 
recurrences. Around the millennium when these successful results were further 
supported by 10-year follow-ups, elective PN become widely accepted [8].  
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Minimallyinvasive methods (MIM) in renal surgery were introduced when Clayman 
performed the first laparoscopic RN (LRN) in 1991, while the first retroperitoneal 
LRN for neoplastic disease was performed in 1994. During the next decade, the 
development of instruments and operative techniques continued, culminating with the 
introduction of the robotic system around the millennium. Robotic-assisted 
techniques facilitated PN with the advantages of three-dimensional magnification and 
endowrist features of the instruments, thereby simplifying resection and suturing 
compared to pure laparoscopic PN (LPN).  
Surgically treatment for RCC is still the mainstay in curative treatment for kidney 
cancer. Even so, the landscape has changed dramatically, from having only one 
treatment (ORN) that should fit all patients to the present management, which 
includes several surgical methods, ablative treatments and surveillance. 
1.2 Epidemiology 
 Incidence and prevalence 1.2.1
KC comprises 2.4% of cancer incidence worldwide [11, 12]. It is the 9
th
 most 
frequent cancer in men and the 14
th
 in women [13]. In 2016, the incidence in Norway 
was 2.7%, whereas between 2007 and 2016, the incidence increased by 52%, from 
574 to 872 patients. Furthermore, the prevalence increased by 77%, from 3,853 to 
6,816 patients [14]. Incidence rates vary considerably, both within Europe and 
worldwide [13]. The Czech Republic and neighboring countries have the highest 
incidence in Europe. The lowest incidence is found in southern Europe (figure 1 and 
2). 
Population growth, changes in age structure and increasing incidence rates account 
for 35%, 35% and 37%, respectively, of the two-fold KC increase seen between 
1990-2013 [15].  
Approximately 34% of all KC was diagnosed in developed countries, and 42% in 
developing countries [15]. The difference may be biased because of cancer 
registration, detection tools, imaging and autopsy rates. The lifetime risk of 
developing KC approaches 3% in the Czech Republic and 1-2% elsewhere in Europe 
[11]. 
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 Mortality and Survival 1.2.2
Of all cancer deaths worldwide, KC accounts for 1.7%, and is the 16
th
 most common 
cause of cancer-specific death [13]. The numbers of deaths have increased for both 
genders and all ages [11], but mortality rates are stable and have declined in high-
resource settings since the 1990s [13]. Interestingly, an 11% decrease in mortality 
rate among women balanced the 15% increase in mortality in men [15], while five-
year relative survival is increasing [12, 13] (figure1-3). The age standardized 
mortality rate in Norway (2016) is 6.4 for men and 2.5 for women [14]. 
 
Figure1: Trends in incidence, mortality and five-year relative survival for Norwegian men and women with 
Kidney Cancer (ICD-10 C64) [14] 
 
 






Age standardized/100 000 
Mortality 2003-2007 
Age standardized/100 000  
Male  Change/10 yr Female 
 
Change/ 10 yr Male  Change/ 10 yr Female Change/10 yr 
Iceland 13.5 0.7 % 8.3 0.1 6.1 0.0 2.8 -2.2 
Norway 10.1 2.5 % 5.3 1.1 3.7 -0.8 1.6 -2.7 
Finland 9.4 0.8% 5.8 -0.3 4.1 -2.7 2.0 -1.2 
Denmark 8.4 3.6% 4.1 1.6 3.9 -1.5 2.0 -2.7 
Sweden 7.1 1.2% 4.4 0.2 3.7 -2.0 2.1 -2.3 
Czech Rep. 22.1 0.8% 9.9 -0.5 9.1 -2.8 3.6 -2.7 
Estonia 16.0 0.4% 6.9 -1.6 7.9 -1.0 2.3 1.6 
Slovakia 15.0 3.1% 7.5 3.5 6.1 -0.2 2.4 -1.0 
Bulgaria 6.7 5.7% 3.0 3.6 3.5  1.2  
France  12.2 1.5% 5.4 1.0 3.6 -0.8 1.3 -3.3 
Austria 11.3 -1.6% 6.1 -2.1 3.3 -3.0 1.7 -3.0 
Netherlands  8.8 1.8% 4.9 1.7 4.0 -1.0 2.0 -1.3 
Australia 10.4 1.0% 5.1 1.2 3.4 -0.5 1.6 -2.0 
New Zealand 9.2 1.7% 4.5 1.5 3.3 -0.1 1.6 -0.2 
Canada  10.2 1.8% 5.7 2.4 3.5 -0.8 1.6 -0.9 
US black 15.2 2.7% 7.3 2.7 3.7 -0.9 1.6 -1.3 
US white 12.5 1.3% 6.7 1.1 3.6 -1.0 1.6 -1.3 
Brazil  7.9 6.8% 5.0 6.4 1.5 2.5 0.8 1.1 
Costa Rica  4.1 3.0% 2.4 2.5 1.6 1.1 0.9 -0.4 
 
Figure 3: Age standardized incidence and mortality for Kidney Cancer [13] 
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 Age and gender 1.2.3





[16]. More KC is diagnosed today among patients older than 70 years: 30% vs. 37% 
(1990-2013) [15]. The incidence is higher in men than women at a ratio of 1.5-2.5:1 
[14, 17, 18], with the incidence increasing more in men than women. Lastly, the 
mortality rate for women is half that of men [12-14].  
1.3 Renal Cell Carcinoma Etiology and Risk factors  
 Inherited RCCs  1.3.1
Most RCCs are sporadic and only 3-5% present with a hereditary cause [19]. The 
hereditary renal cancer syndromes (HRCS) have a defined genetic mutation, while 
familial non-syndromic renal cancers (FNSRC) have a multi-genetic inheritance 
caused by a combination of genes. Hereditary RCC should be suspected, and genetic 
counseling offered in patients with early-onset RCC (<40 years), a familial history of 
RCC, bilateral or multiple tumors. Knowledge of non-renal manifestation of HRCS is 
important. Currently, 10 HRCS, all with autosomal dominant inheritance, are 
described.  Von Hippel Lindau (vHL) is the most common HRCS. Approximately 
70% present with ccRCC before the age of 70, with multiple and bilateral tumors, in 
addition to non-renal manifestations [19, 20]. FNSRC present with a single RCC in 
more than one first- or second-degree relative and they can skip a generation [21]. 
They typically have an early onset (<50 years), and are often multiple or bilateral 
[22]. 
 Tobacco  1.3.2
Smoking increases the risk of RCC dose-dependent, and more so in men than women. 
Cessation reduces the risk substantially [23, 24]. Smokers present with more 
aggressive phenotypes and at higher stage [24], and smoking has a negative impact 
on survival [25]. Among men and women, 21-30% and 9-24% of RCC is attributed to 
smoking [15, 17]. Most of the constituents in cigarette smoke are metabolized or 
excreted through the urinary tract. RCC predisposition is comprised of nitrous-
compounds, the formation of oxygen-free radicals [24], smoking-related chronic 
tissue hypoxia [26] and to be a slow-acetylator genotype [17]. 
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 Body Weight  1.3.3
Obesity increases the risk of RCC. In Europe and in the US 30-40% of RCC is 
attributed to overweight [26, 27]. A Norwegian study confirms the correlation 
between body mass index (BMI) and RCC, and the risk is dose-dependent [13, 28, 
29]. Paradoxically, obese patients present with lower grade and stage RCC, and have 
better cancer specific survival (CSS) and overall survival (OS) [30, 31]. The complex 
interplay between obesity and RCC involve inflammation, tissue hypoxia, lipid 
peroxidation, VHL mutation, increased production of insulin-like- and other growth 
factors [32]. The adipose tissue-derived hormones, adiponectin and leptin, are linked 
to more aggressive RCC in low and high levels, respectively [32].  
 Kidney Disease and Hypertension  1.3.4
Patients with acquired cystic kidney disease (ACKD) present more than six-fold higher 
incidence of RCC[16] compared to the general population. After renal transplantation, native 
kidneys also have a higher incidence of RCC [17, 33]. Hypertension and antihypertensive 
drugs as risk factors for RCC are hampered by the fact that it is difficult to separate the 
effects of each [16, 17]. However, the EPIC study documented a positive relationship 
between RCC and systolic and diastolic blood pressure [34]. 
 Other risk factors  1.3.5
Occupational high exposure to asbestos, trichloroethylene, cadmium and lead in the metals 
industry [35-38] are linked to increased risk, as is chronic exposure to arsenic in drinking 
water [17]. A high protein diet and fatty food are linked to an increased RCC risk[16] 
whereas an intake of fruit and vegetables is protectable [17, 39].  
1.4 Classification of Kidney Cancer 
 From Renal mass to Kidney Cancer and Renal Cell 1.4.1
Carcinoma 
A practical approach and the everyday challenge for clinical urologists, radiologists 
and pathologists is to differentiate between malign, benign and inflammatory renal 
masses (figure.4). Renal masses might be classified by either histopathology or by 
imaging. The latter uses the radiographic appearance to denominate a renal mass as 
simple cystic, complex cystic, fatty tumors and other solid lesions [40].  
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 Histopathological Classification of RCC 1.4.2
There has been a significant development from the first morphology based 
(Heidelberg) classification in 1997 [6] to the latest update on renal neoplasia by 
ISUP/Vancouver 2012 and WHO 2016 [33, 41, 42]. Several new entities have 
emerged, and existing tumors have been refined during the last decades [43]. Today, 
17 morphological types of renal malignancy are characterized. Classification is based 
on predominant cytoplasmic-, staining- and architectural features, cell type, anatomic 
location, genetics or a combination of all these features [6, 33, 41].  
Clear cell renal carcinoma (ccRCC), arising from the proximale tubule constitutes 75-
80%, papillary renal cell carcinoma 
(pRCC) 10-18%, chromophobe renal 
cell carcinoma (chRCC) 5%, collecting 
duct carcinoma 1%, whereas 3-5% 
remains unclassified [44].  
Furthermore, pRCC is subdivided into 
type 1 and 2, representing low and high-
grade, respectively, and is related to 
prognosis. The molecular heterogeneity 
of type 2 is not fully characterized, but 
several subtypes emerge [42, 45]. Since 
2016, the term papillary adenoma, with 
a low malignancy potential, is used for 
low grade papillary tumors ≤15 
millimeters[41]. 
 Cystic Renal Lesions  1.4.3
Renal cysts are common, with most 
benign and asymptomatic. The Bosniak 
classification (BC) introduced in 1986 
simplified the differentiation between 
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Figure 4:  From Renal Mass to Renal Cell Carcinoma  
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complex (BC type II-IV) cysts, which could harbor carcinoma. The classification is 
based on morphology and enhancement characteristics on contrast-enhanced CT. The 
system was quickly adapted by radiologists and urologists [46, 47].  
 BC type I–II cysts are invariably benign. The BC type IIF represents a subgroup, in 
which approximately 5-7% will develop RCC. Regular follow-up(FU) is needed, 
during which 12% will be upgraded to BC type III [46].  Resected BC III and IV 
cysts turn out to be RCC on final histopathology in 51% and 89%, respectively. 
However, they tend to be of a low stage and low grade, and thus a low potential to 
metastasize. Hence, these tumors carry a good prognosis [48, 49].  
 Non-renal malignancies in the kidney  1.4.4
Lymphomas may present hypovascular multiple renal masses on CT, either as a 
solitary mass or a diffuse renal infiltration [50]. Patients with atypical or massive 
lymphadenopathy, splenomegaly, immunosuppression, autoimmune disease or B-
symptoms should undergo a renal mass biopsy in order to avoid unnecessary surgery 
[51]. 
Sarcomas account for 1% of KC, and should be suspected when there is a rapidly 
growing mass with the presence of fat or bone. The prognosis is generally poor, even 
when the wide-margin RN and en bloc excision of adjacent organs are performed and 
combined with adjuvant chemotherapy.  
Only 3% of Wilms tumors are in adults, and should ideally be treated after protocols, 
as for pediatric Wilms tumors. However, an adult Wilms tumor is often an 
unexpected finding at final histopathology [51]. Other rare renal tumors include 
carcinoid, small-cell carcinoma and primitive neuroectodermal tumors, of which the 
latter two require multimodal therapy [51]. 
Renal metastases predominately have a pulmonary or colorectal origin [50, 52]. They 
typically present asymptomatic, with two-thirds as a solitary nodule and the rest 
being multiple or bilateral. The interval between the primary cancer 
diagnosis/treatment and metastases can be substantial [53].  
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 TNM-classification   1.4.5
The TNM classification describes the anatomic extent of malignant tumors. This 
staging based on tumor, nodes and  metastases was launched  as a cooperation 
between the Union for International Cancer Control  (UICC) and the American Joint 
Committee for Cancer Staging and End Results Reporting (AJCC) [54]. Today, this 
has replaced older staging systems for KC [55].  
There have been several revisions over the last few decades. Such revisions are based 
upon new knowledge for the ability to predict progression and survival. Among the 
present candidates for upcoming revisions, there are the questions of whether T1 and 
T2 should be further sub-classified, as well as whether sinus fat invasion may exhibit 
a worse prognosis than perinephric fat invasion. Presently, both are classified as T3a.  
Finally, there is an ongoing discussion if microscopic (in addition to macroscopic) 
vein-, hilar sinus and pelvicalyceal system invasion should be classified as T3a. This 
latter discussion has caused discrepancies between the last TNM revisions from 
UICC and AJCC [42, 56, 57].  
 Histopathological Grading of Renal Cell Carcinoma 1.4.6
 Nuclear Grading 1.4.6.1
Fuhrman et al. published their nuclear grading system in 1982. They based their 
system on tumor aggressiveness (nuclear size and prominence, in addition to 
nucleolar prominence). The system is evaluated according to survival and 
prognosis[58]. Validation, interpretation and reproducibility of this system have been 
problematic, although the system is still widely used. WHO and ISUP/ Vancouver 
(2016/2012) have proposed a new four-tier grading system based only on nuclear 
prominence. The highest grade should be reported [41, 42]. It has been validated as a 
prognostic marker for ccRCC and pRCC, and its use has also been accepted to 
describe other morphotypes of RCC. However, for chRCC, an improved grading 
system is needed [41, 59]. 
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 Presence of Necrosis 1.4.6.2
The microscopic appearance of coagulative necrosis predicts a worse prognosis for 
ccRCC and chRCC [42]. Outcome in pRCC is not related to necrosis, as the tumors 
likely are predisposed  to undergo spontaneous necrosis [59]. Necrosis is also 
incorporated in various prognostic models [60, 61]. 
 Sarcomatoid features  1.4.6.3
Sarcomatoid features can be identified in all RCC subtypes, and is not a separate 
entity. Any presence of such features offsets an ISUP grade four score. Moreover, the 
greater the proportion is, the worse the prognosis [42, 62].  
1.5 Diagnostic Work–Up in KC Management 
Among others, mode of presentation, symptoms, the patient’s medical history, 
performance status, laboratory findings, image-defined clinical tumor stage and 
burden are all important features for the evaluation of a KC patient during the 
pretreatment work-up. As 80% of patients present with localized disease, and are thus 
candidates for curative management, stratification according to patient risk of 
recurrence or metastasis helps the surgeon in decision-making, and in counseling the 
patient regarding treatment. 
 Clinical presentation and Symptoms  1.5.1
Today, incidentally detected tumors represent the majority, increasing from 7% to 60-
70% over the last 50 years [63-65]. A more widespread use of imaging is among the 
reasons for this. It is not only imaging for newly arisen back-, flank- or abdominal 
pain, but also imaging for FU for both cancers and chronic diseases, which has led to 
this increased discovery. Because most of these tumors are small, there has been a 
“stage migration” in KC over this period of time. 
The classic triad of flank pain, hematuria and a palpable tumor is infrequently seen 
today, though one or two of the symptoms is not unusual[66]. Moreover, obstructing 
venous thrombus can cause varicocele or lower extremity lymphedema.  
Patients may present with symptoms from local tumor growth, tumor bleeding (with 
gross hematuria), paraneoplastic manifestations or metastatic disease. 
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A tumor can produce hormones, peptides, cytokines and inflammatory mediators, 
hence causing paraneoplastic syndromes in up to 20% of the patients [67]. These 
substances may induce weight loss, cachexia, fever, anemia, hypertension, 
neuromyopathy, amyloidosis, hepatic dysfunction and polycythemia, plus lowered 
albumin, elevated ESR and CRP [68, 69]. 
Coughing or dyspnea are symptoms of lung metastases. Cerebral metastases may 
present as confusion, dizziness or epileptic seizures, while bone metastasis most often 
debuts with pain or a pathological fracture (e.g. femur, humerus or vertebra). Since 
RCC has a diverse metastatic pattern, metastases may appear in almost all organs or 
regions of the body (i.e. a vaginal, parotid or pancreatic tumor, a skin nodule or 
supraclavicular nodes) [41]. 
 Physical examination and Laboratory findings  1.5.2
A complete medical history, including an evaluation of the severity of comorbidity, 
previous surgery, family history and medication, is crucial during a diagnostic work-
up. The physical examination, including a consideration of patient age, compliance, 
cognitive function and wishes, is also of imperative importance.  
It is essential to question whether the patient will actually benefit from surgery, and 
consequently to assess the risk in conjunction with the surgical procedure.  
Based on the information gathered from medical history and a physical examination, 
preoperative expanded investigations or necessary medical treatment must be 
scheduled if needed to help optimize patients before surgery.  
A blood test should always be evaluated preoperatively, and blood for standard 
surgical blood assays should be drawn. In addition, blood tests such as ESR, CRP, 
hemoglobin (Hb), complete blood cell count, alkaline phosphatase (ALP), lactate 
dehydrogenase (LDH) and S-calcium carries prognostic information.  Proteinuria, S-
creatinine and estimated GFR all aid predicting  postoperative renal function [70].  
 Quality of Life 1.5.3
The patient’s non-oncological Quality of Life (QoL) should be considered in 
conjunction with oncological outcomes in decisions for treatment [71]. QoL is 
influenced of sociodemography, comorbidity, psychological factors and the extent of 
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the cancer disease. In the short term, it is related to pre-, intra- and postoperative 
factors, including patient counselling, plan of management, experience of support, 
lack of complications and adequate follow up (FU).  
 Performance status, Comorbidity and Risk of complications  1.5.4
Patient performance status is most commonly scored by the Karnofsky Performance 
Scale (100-0) or the Eastern Cooperative Oncology Group Index (ECOG 0-5)[72]. 
The American Society of Anesthesiologists created the ASA score (I-VI) to 
communicate the physical status of a patient in order to roughly predict the anesthetic 
risk and outcome. The Charlson Comorbidity Index preoperatively evaluates and 
integrates system-affecting comorbid illnesses in such a way that the scoring predicts 
outcome after treatment [73].  
 Kidney function  1.5.5
Efforts should be made to preserve kidney function. This is especially important in 
patients with ongoing impaired kidney function, diabetes mellitus or hypertension. 
The Glomerular Filtration Rate (eGFR) should be calculated from the CKD-EPI 
equation, and not only with s-creatinine, since 30% of patients with normal s-
creatinine have pre-existing Chronic Kidney Disease (CKD) [74]. CKD represents a 
dose-dependent risk factor for cardiovascular events, hospitalization and mortality of 
any cause. Furthermore, this is independent of earlier known cardiovascular disease 
or proteinuria, with the rate of adverse events abruptly rising when the 
GFR<45ml/min/1.73m
2
 [75]. Surgically induced CKD may worsen existing medical 
CKD. New-onset CKD is more likely to occur, and pre-existing CKD may progress 
faster in patients undergoing RN than PN [74, 76]. The only randomized study 
(EORTC) could not document a survival benefit for PN compared to RN[77]. Other 
presented data show improved assumed to partly be attributable to the preservation of 
renal function [78, 79] by reducing cardiovascular events [80].  
 Imaging  1.5.6
Imaging is essential in KC diagnostics, staging and FU. The quality of various 
imaging modalities has continuously improved over the past few decades. Contrast-
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enhanced imaging with CT and MRI constitutes the basic modalities today, although 
intravenous urography, venography and angiography are seldom used in modern 
practice.   
 Computed tomography  1.5.6.1
High sensitivity and specificity in detection earned the helical multi-slice computed 
tomography (CT), which has been the gold standard for RCC-imaging from the 1990s 
onward [70, 81]. Today, the more precise multidetector CT (MDCT) has replaced 
helical scanners, with a short acquisition time, reduced motion artefacts and ultrathin 
sections, preferably 1.5-3 mm. The vascular- and collecting system is better 
demonstrated by reformatted images. MDCT is also regularly used for staging, 
surgical planning, treatment-evaluation and FU. Newer techniques such as dual-
energy CT (DECT), using virtual non-contrast (VNC) imaging and iodine 
quantification maps can reduce the radiation dose by 35-47% [82]. Functional 
imaging such as perfusion CT (pCT) is relevant in response evaluation and looks at 
tumor angiogenesis by describing blood flow/volume, transit time and permeability 
[83]. However, more studies are warranted before both these recent modalities can be 
routinely used. 
For modern primary diagnostics, an MDCT with four phases is preferred [70].  
The non-contrast phase establishes the baseline (solid lesion: >20HU, fat as in 
angiomyolipoma (AML) : < -10HU, cysts: -10-20 HU, high density cysts: > 40 HU).   
The arterial phase (20-40s after contrast injection) maps renal artery anatomy, aiding 
in preoperative planning. Enhancement is related to vascularity. An increase of >15-
20 HU in the arterial or nephrographic phase may indicate malignancy in both solid 
tumors and complex cysts.  
Detection is more sensitive, more specific and more accurate in the nephrographic 
phase (70-100s after contrast injection) [84].  
The excretory phase (seven min after contrast injection) illustrates the collecting 
system, and thus an eventual intrusion of this. 
 25 
Today, the radiology report is supposed to describe size, necrosis, calcifications, 
enhancements and location of the tumor. Though accurate, CT has interpretative and 
technical pitfalls [84]. Small and fat-poor AML is difficult to diagnose with CT and 
MRI, thereby making biopsy necessary [85, 86]. The spill-in effect from nearby renal 
tissue and a small region of interest (ROI) makes it more difficult to characterize 
small renal lesions. Kidney function, cardiac output and volume and rate of contrast 
administration may affect contrast enhancement. Contrast enhancement is suggestive, 
but not diagnostic for the type of solid lesion.  
For RCC staging, axial imaging depicts adrenals, lymph nodes, involvement of 
organs, lumbar vertebras, veins (renal, gonadal, lumbals, vena cava inferior, hepatic 
veins), thrombus level and visible collateral veins. An evaluation of the extension of a 
bland thrombus is difficult on CT. Signs of locally advanced disease includes the 
thickening of Gerotas fascia, the presence of collateral vessels in the peri- and 
paranephric fat [87]. To determine the eventual perinephric fat invasion is 
challenging with CT, and may be better visualized by MRI. The chest CT is routinely 
performed in primary staging, looking for pulmonary, pleural or mediastinal 
metastases. 
To avoid a worsening in patients with kidney failure, an iodine contrast should be 
used with caution. One solution to this is a non-enhanced CT or MRI and US 
combined with a renal mass biopsy.  The dose of irradiation with repeated imaging 
remains a concern, especially in young patients. 
 Magnetic Resonance Imaging (MRI)  1.5.6.2
MRI is rendered equal to CT in order to characterize renal masses [70]. MRI may be 
offered to pregnant women and patients with iodine-contrast allergies. Furthermore, 
the use is indicated if CT is indeterminate, as with some small lesions, cysts and low-
enhancing renal masses [81, 88]. For staging, MRI may be better for the detection of 
perirenal fat invasion, and for the determination of the extension of a venous 
thrombus[70]. MRI is the preferred modality for the detection of metastases to bone 
[89] and also for the FU of patients with von Hippel-Lindau disease [70, 81]. 
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Hopefully the non-contrast enhanced diffusion weighted imaging (DWI) can expand 
its role[90]. In particular, DWI could offer advantages in patients with severe CKD 
and ACKD, differentiating pseudotumors and solid lesions among multiple cysts [91, 
92]. 
 Renal ultrasound  1.5.6.3
Renal ultrasound complements other imaging methods. A renal lesion detected with 
ultrasound, grey scale modus (US) should always be investigated with an up-to-date 
CT scan.  
US may serve as an option for surveillance, the evaluation of tumor growth, image-
guided biopsy and therapy, and to define whether a lesion is cystic or solid. It could 
complement non-contrast CT when contrast agents are contraindicated. US is inferior 
to CT to detect small renal lesions, although sensitivity increases with tumor size. 
The sensitivity for lesions 15-20 mm and 25-30 mm was 58% and 100% for US vs. 
100% and 100%, for CT, respectively [93]. 
Contrast-enhanced ultrasound (CEUS) has a high sensitivity and specificity for renal 
lesions [70], and illustrates the vascularity of the lesions. CEUS can better than US in 
differentiating solid components in cystic lesions, but is inferior to MRI.  
Color Doppler US may aid in the verification of thrombus-extension into the inferior 
vena cava [81]. 
To identify the level of supradiaphragmatic caval thrombus (level III/VI), 
transesophageal ultrasound (TEUS) is a commonly used modality. TEUS has a 
diagnostic accuracy of 85% vs. MRI 90% [94]. The result of TEUS can affect 
surgical management concerning the use of cardio-pulmonary bypass and level of 
clamping [95]. 
Both in open and laparoscopic renal surgery, intra-operative ultrasound (IOUS) is of 
great importance to locate intrarenal tumors, depict tumor margins, and reveal 
additional renal lesions. Thus, it influences and may alter surgery [81, 96]. 
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Finally, US is highly operator- and patient-dependent, so the results must therefore 
always be interpreted with this in mind [93].   
 Targeted imaging  1.5.6.4
To stage sarcomas and lung carcinomas, 
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F-fluorodeoxyglucose-positron emission 
tomography (FDG-PET) combined with low-dose CT, is the standard method [97, 
98]. However, there is no such recommendation for primary RCC staging. This is due 
to a low sensitivity (47%-60%) that limits the diagnostic performance [70, 97]. In 
locally advanced metastatic or recurrent disease, PET may supplement CT [97]. 
Noteworthy is that a negative PET does not exclude advanced disease, though a 
positive scan has a strong positive predictive value. Recent publications support a 
role for FDG–PET in restaging, but it does not necessarily detect all metastatic 
lesions. False positive results can be benign tumors, inflammatory disease or 
postoperative scarring [98, 99].  





C-acetat are still under consideration for regular use [81, 100].  
 Other available imaging modalities  1.5.6.5
RCC bone metastases are predominantly osteolytic with a poor osteoblastic response. 
The bone scintigraphy with Technetium-99m methylene diphosphonate (
99m
Tc-MDP) 
has a specificity of 94%, but is not recommended in staging because of a sensitivity 
of only 60% [70, 89]. To assess split renal function, and to predict the glomerular 
filtration rate after surgery, a MAG3 scan can be performed[70] . 
 Anatomical scoring systems  1.5.7
To determine the feasibility of PN vs. RN, urologic surgeons need detailed 
information about tumor size, multifocality, depth, nearness to hilar structures and 
collecting system, renal vascular anatomy and location (anterior/posterior/ 
upper/lower/middle). Anatomical scoring systems (ASS) provide a common language 
for standardizing tumor assessment. A high score indicates a more complex location, 
and PN is performed with a higher risk of complications. The cut-off values for PN 
can differ according to the surgeon’s experience and surgical technique. Several ASS 
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(figure 5) have been suggested over the last decade, and several have been compared 
and tested (inter-observer reliability). For all, a higher score was associated with a 
longer warm ischemia time, a higher postoperative creatinine level, a larger tumor 
size and an increased risk of perioperative complications [101].  
Anatomical Scoring System Description Author 
Renal Nephrometry Score Radius, Exophytic/endophytic, Nearness, 
Anterior/posterior Location) 
Kutikov 2009 [102] 
PADUA  Preoperative Aspects and Dimensions 
Used for Anatomical  location 
Ficarra 2009 [103] 
C-Index Centrality index (continuous) Simmons 2010 [104] 
RTII Renal tumor invasion index Nisen 2015 [105] 
Contact Surface Area Contact area between tumor and 
surrounding tissue 
Leslie 2014 [106] 
Zonal Nephro Scoring System Nearness, physical location, 
radius,organization 
Hakky 2014 [107] 
ABC Scoring System Arterial Based Complexity Spaliviero 2016 [108] 
 
In daily practice, ASS combined with a patient’s feature and surgeon’s experience 
can optimize surgery [109]; however, the implantation in routine use is questioned 
[101, 110]. To make ASSes usable, the scoring system must be easy to use in a 
preoperative setting and not too time-consuming. As most studies that have used ASS 
have done so retrospectively, one might question the actual real-world use of the 
systems. Today, most are used as a tool to improve the communication of surgical 
results and patient selection.  
 Other related factors that influence the complexity of surgery 1.5.8
A thick layer of or adherent perinephric fat represents a challenge to surgeons in 
regard to mobilizing the kidney, and identifying the renal vessels and the tumor. All 
these factors are related to increased blood loss and an increased operative time [111].  
Renal vascular variants as accessory arteries, early branching and existence parallel 
branches that could lead to an incomplete clamping and excessive bleeding, thereby 
compromising the operative field. Common venous variants, such as multiple renal 
Figure 5: Different Anatomical scoring Systems 
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veins, late venous confluence, circum-aortic or retro-aortic veins, may cause 
operative problems if they are not identified preoperatively [112, 113]. 
 Prognostic factors and nomograms  1.5.9
Prognostic factors can either independently predict CSS and RFS, or they can be 
combined in a nomogram. The factors must discriminate between favorable and 
unfavorable RCC phenotypes, and be applicable to clinicians and for all patients . 
Incidentally detected tumors have a better prognosis than symptomatic RCC [65], 
while patients with local symptoms do better than patients with systemic 
manifestations [63]. Symptoms like weight loss, anorexia, malaise and reduced 
overall health all negatively impact survival. 
The TNM staging system provides prognostic information based on anatomical 
characterization. CSS is shorter with higher stage, nodal and metastatic disease [54, 
70]. Measurements of systemic inflammation independently predict survival for both 
localized and metastatic RCC. These are thrombocytosis, neutrophil/lymphocyte-, 
monocyte/lymphocyte- or platelet/lymphocyte ratio, hypercalcemia, elevated ESR, 
CRP, ALP, LDH, lowered Hb and Glasgow prognostic score. Several of these are 
implemented in predictive models, and those not implemented may provide 
complementary information to clinicians. 
 Pretreatment prognostic nomogram for non-metastatic RCC  1.5.9.1
Different preoperative nomograms for prognostication have been developed. The 
model suggested by Karakiewicz et al. included age, gender, symptoms, size, CT 
stage and metastasis in regard to CSS [114].  
Raj et al. incorporated gender, mode of presentation, nodes, necrosis and size at 
imaging to predict recurrence free survival or metastatis free survival (MFS) [115].  
The prognostic model proposed by Hutterer predicts the presence of lymph nodes 
metastasis, in order to identify patients who profited from a lymphadenectomy [116].  
Kutikov and Hollingsworth included preoperative comorbidity in their models, and 
focused on other-cause and other-cancer mortality in addition to CSS [117, 118].  
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To aid selection for major surgery in patients with supra-hepatic tumor-thrombus, 
Haddad et al. developed a model to predict survival and major complications [119]. 
 Pretreatment Prognostic models for mRCC  1.5.9.2
Models from the Memorian Sloan Kettering Cancer Centre (MSKCC) and the 
International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) are the 
two most widely used prognostic models in conjunction with mRCC. The MSKCC 
model was originally developed in the cytokine era. RCC patients were stratified 
based on Karnofsky <80%, low Hb, high LDH, high corrected S-calcium and no prior 
nephrectomy , into good (0 factors), intermediate (1-2 factors) and poor–risk (≥3 
factors) [120]. Later, in the targeted therapy era, the IMDC model was created by 
adding elevated neutrophils and thrombocytosis to the stratification, and changed no 
prior nephrectomy to >1 year between diagnosis and targeted therapy treatment. 
However, the same risk-grouping model was used [121]. The IMDC model predicts 
an OS in the favorable-,  intermediate- and poor-risk group of 43, 23 and 8 months, 
respectively [121].  
Other models exist but are less used [122-124]. Furthermore studies have 
demonstrated that patients with metastasis to bone, liver or the brain have a worse 
prognosis [125]. Even if the models are established for ccRCC, at the current time the 
same prognostic criteria apply for all subtypes of mRCC [126].   
 Pretreatment Biopsy and FNAC  1.5.10
Renal mass biopsies (RMB) were initially indicated in patients with other primary 
malignancies, solitary kidneys, older age and multiple comorbid conditions [127]. 
The rising interest and importance in RMB is due to an increased detection rate of 
small renal masses (SRM), the introduction of active surveillance (AS) [128], 
ablative treatments (AT) and novel targeted therapies in metastatic disease [70]. Since 
a significant number of SRM are benign [129, 130], a RMB with a benign 
histopathology can spare patients from unnecessary surgery [128, 131, 132].  
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RMB is not indicated for patients with a limited life expectancy, severe comorbidity 
and low performance when surgical-, ablative- or targeted systemic treatment is not 
an option, or for patients with advanced disease in a palliative setting [70, 133].  
RMB are usually performed image-guided; two cores biopsies (CB) with a co-axial 
technique and 18-Gauge needle. To ensure an adequate tissue core, quality can be 
assessed immediately [133-135], as CB seems to have a better diagnostic yield than 
Fine Needle Aspiration Cytology [136]. Complications are mostly minor and limited, 
resolving without any intervention [131, 132, 134, 136]. The co-axial technique has 
reduced the worry of seeding [136] 
The distribution of diagnostic (DCB) and non-diagnostic biopsy (NCB) is typically 
80% vs. 20% [134]. Because the rate of malignancy in non-diagnostic CB may reach 
80%, a re-biopsy is reasonable in most cases [132]. However, it should be kept in 
mind that the result of re-biopsies may be indeterminate [137]. The diagnostic yield is 
lowest in small and endophytic lesions [131]. Additionally, anterior-, upper-, medial- 
and perihilar-located lesions may demonstrate higher rates of non-diagnostic CB 
[133]. In cystic lesions, the use of CB should be limited to definite enhancing areas as 
in BC type IV cysts [70, 133], while in large tumors peripheral necrotic areas should 
be avoided. The overall ability to differentiate malignant from benign lesions, and to 
determine subtype is good: 81-97% and 86-98%, respectively, but accuracy for tumor 
grading is lower [133, 136], as is the estimate of sarcomatoid elements [138].  
1.6 Management of RCC 
Surgical treatment for RCC has been a subject for changes since the late 1980s, and 
from having only open RN on the surgical repertoire, the treatment options in 2018 
include several alternatives. Since the first laparoscopic nephrectomy in 1991, 
refinement of surgical techniques and the further development of minimally invasive 
methods have revolutionized patient care. Hand-assisted laparoscopic techniques, 
laparoscopic endoscopic single-site surgery (LESS), natural orifice transluminal 
endoscopic surgery (NOTES) and hybrid techniques have evolved [139-142], but 
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have not gained the same popularity and become as widespread as robot-assisted 
laparoscopy [143].  
During the last few decades nephron-sparing treatment has developed as an 
alternative to RN for localized disease. The increasing incidence of RCC [14], 
unsuspected benign histopathology [129], surgically induced impairment of renal 
function [74], an increased prevalence of medical CKD, and its relation to metabolic- 
and cardiovascular disorders and events [75], constitute the background for this. 
Ablative treatment and surveillance may also be used to preserve renal function and 
limit morbidity. 
 Management of Localized RCC (cT1-2) 1.6.1
1.6.1.1 Nephron-sparing surgery  
From the initially imperative indications for PN, current European guidelines 
recommend nephron-sparing treatment whenever feasible for tumors ≤ 7 cm, as long 
as the trifecta of PN with negative margins, functional preservation and minimal 
complications can be maintained [70, 127, 144]. Former absolute and relative 
indications still apply for single kidney, bilateral tumors and multifocal tumors, 
impaired function in contralateral kidney or renal compromising diseases, such as 
diabetes and hypertension. PN is demonstrated to be oncological equivalent to RN for 
tumors ≤ 7 cm [145, 146]. 
Earlier open surgical access was the gold standard for PN, and performed through a 
flank, subcostal or midline approach. Laparoscopic PN was introduced in 1994, and 
from the beginning was associated with longer ischemia time and a higher rate of 
complications. Around 2003, the first robot-assisted laparoscopic PNs (RALPN) were 
performed, and RALPN soon became popular among surgeons because of a shorter 
learning curve and greater instrument flexibility [147, 148]. OPN, LPN and RALPN 
are now equitable procedures, with the two latter mostly performed with intra-




The Key Surgical steps are the same for all PN-methods  [40, 149]: 
1 - Mobilization of the kidney within the Gerotas fascia to permit adequate resection. 
2 - Sufficient access to the hilum for vascular control, and to identify arteries, veins and ureter. 
3 - Location of the tumor and preservation of perirenal fat overlying tumor(s). 
4 - Arterial clamping: The quality of the remaining parenchyma is better preserved with a short 
ischemia time [150]. An accepted cut-off for a warm ischemia-time is 20-25 minutes [151]. If a 
longer time is needed, the use of cold ischemia can increase it to 35-44 minutes [40, 152]. Cooling 
with ice slush is easily obtained for OPN. Clamping of the renal artery during resection reduces 
blood loss and visualizes tumor margins to help safely complete the resection and renoraphy [40] 
To reduce global ischemia, additional concepts, such as early unclamping [153], zero ischemia 
with segmental clamping [154], parenchymal clamping [40] and off-clamp procedures [155] have 
evolved. The preferred method depends on surgeon preference. The renal preventive role of 
intravenous mannitol infusion before clamping is debated and controversial [156]. 
5 - Tumor excision with free margins: Large, complex or endophytic tumors lead to more 
devascularized parenchyma than small, simple and peripheral tumors [157, 158]. 
Negative margins are oncological adequate, with no need for an additional parenchymal rim. 
Tumor enucleation, including the tumor pseudocapsule, reduces excised normal parenchyma, 
bleeding and ischemia time [159].  
Biopsies of resections surface to ensure that free margins are seldom used [160]. 
6 - Renoraphy and reconstruction of the collecting system: Closing of the collecting system with 
an absorbable suture to avoid urinary leakage. Renoraphy is most often performed with a running 
inner suture for hemostasis and an outer parenchyma-closing suture. Hemostatic agents may also be 
applied at the resection surface.  
 Radical nephrectomy 1.6.1.1
RN can be performed when PN is not feasible, i.e., a non-functioning kidney, an 
insufficient renal remnant, renal vein or caval thrombosis, complex tumor location 
and when comorbid with a need for anticoagulants [70]. 
Depending on tumor size, patient habitus and the surgeon’s skills a surgical approach 
is determined, but if possible MIM-RN is preferred for T2a, though for a large tumor 
like T2b an open approach is often preferred. 
ORN and LRN share the same operative principles with early vascular control, the 
removal of the kidney with an intact Gerotas fascia and the avoidance of specimen 
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traumatizing as the key steps. They are found to be equivalent concerning long-term 
oncological results [161]. The advantages of LRN were soon recognized by both 
surgeons and patients, and included shorter hospital stays, faster convalescence, less 
use of analgesia, less bowel symptoms and improved cosmetics [71]. Regarding 
perioperative outcomes, LRN could be a good alternative in elderly patients or 
overweight, though also more challenging in the obese patients [162]. 
An intact specimen is extracted in an impermeable bag through a Pfannenstiel 
incision, or a muscle-splitting extension in conjunction with one of the ports. Robot-
assisted LRN is not as widespread as RALPN, partly due to the expenses. 
Open RN is usually performed with an intra-abdominal approach (subcostal or 
midline incision). A retroperitoneal approach maybe preferred in patients when the 
intra-abdominal is complicated or inaccessible (i.e. severe adhesions).  
 Ablative treatment  1.6.1.2
Ablative treatment (AT) destroys tumors and saves renal parenchyma. 
Radiofrequency ablation (RFA) and Cryoablation (CA) are mostly used, but high-
intensity focused ultrasound (HIFU) and microwave therapy also exist. Guidelines 
recommend AT for tumors < 3 cm [70, 163], but is also tried on larger ones [164]. 
AT is an option in patients not suitable for surgery, and currently RFA and CA show 
comparable MFS and CSS [164-166]. In a recent meta-analysis, renal function after 
AT and PN is reported to be similar [167]. A biopsy should be obtained before or 
during ablation, since there is no final histopathology specimen. Recurrences are 
slightly more frequent than PN; however, while retreatment after AT is a viable 
option [165, 166, 168], whereas surgical salvage after PN is surgical challenging 
[169].  
 Active Surveillance  1.6.1.3
Active surveillance (AS) comprises the combination of initial observation with 
repeated imaging, with a delayed intervention performed if rapid growth or clinical 
progression occurs in small renal masses (SRM) [170].  
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Most SRM grow slowly: 0.2 – 0.6 cm/year, few are high grade (5% of <3cm) and the 
metastatic potential is low [171-174].  Recommendations call for risk stratification 
based on age and competing causes of mortality, as well as renal mass biopsy for AS 
candidates to help prevent unnecessary overtreatment [70, 170, 175]. Delayed 
intervention does not limit or complicate eventual treatment [176]. Delayed treatment 
is usually considered when the doubling time is <1yr, the growth rate is 1 cm/year or 
the tumor reaches 3-4 cm in diameter [170] .  
Non-RCC related mortality after surgery for SRM is significant in older 
patients.[117]. For patients > 70 yrs with surgically treated RCC < 4 cm, 40%  died of 
non-RCC causes during the first five years [118]. AS is regarded as a safe 
management for old and comorbid patients [70]. For patients with larger tumors and 
severe competing risks, AS might be considered as an option, though the risk of 
metastases increases [177].  
If comorbidity and compliance render active treatment contraindicated, the patient is 
not a candidate for AS. In such cases, watchful waiting with symptomatic and 
palliative treatment when needed is a better strategy [70, 178].  
 Management of Locally Advanced RCC (cT3a-c)  1.6.2
RN is the recommended treatment for T3a with perinephric fat invasion. The 
management of T3a with venous extension is more complex, with the procedure 
ranging from almost a standard RN for a small renal vein thrombus to 
cardiopulmonary bypass (CPB) for right atrial thrombus [179]. Both the thrombus 
level and degree of occlusion impact the choice of surgical approach (figure 6). 
Grouping systems are made for venous tumor thrombi (0-IV) and for blend thrombi 
(A-D), to aid management [180, 181].  In older series, the incidence of thrombus in 
vena cava inferior (IVC) is reported to 4-10% [40, 181, 182]. Prognostic factors for 
survival after surgery are PS, TNM, level of thrombus [119], invasion of the renal 
vein wall, diameter and rounded vs. fragile appearance of the thrombus [183].  
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Level of RCC Tumor Thrombus  (TT) after Blute [181] 
TT-Level Incidence % of TT Cranial extent of  TT Management of TT 
0 12% 65% Renal vein Minimal modification of standard approach 
I 2% 10% Within < 2cm over  
renal vein ostium 
Milking of TT,  clamping of IVC, contralateral 
renal vein, lumbals 
II 3% 15% Below hepatic veins Clamping of IVC below and above, 
contralateral renal vein and lumbals 
III 1% 5% Between hepatic veins 
and diapragm 
Clamping depends on complete or partial 
occlusion, liver mobilization,  VVP, CPB, 
DCA 
IV 1% 5% Above diaphragm CPB, VVP, DCA 
Figure 6: CPB – cardiopulmonal bypass, VVP  - venovenous bypass, DCA – deep cardiac arrest 
 
Patients with M0 and good PS should be offered radical surgery, since five-year CSS 
is 18-68% with complete resection [184, 185]. Unfortunately, in patients with VTT 
synchronous M1 is frequent (25-63%). Complications and mortality is 30% and 3-
8%, respectively. Thus, preoperative patient counselling is important [181]. 
Furthermore, these procedures need careful preoperative planning, often with the 
involvement of an experienced anesthesiologist, vascular-, thoracic- and 
liver/transplant surgeons [184]. Preoperative renal artery embolization or an IVC 
filter is not recommended [70, 181, 184].  
 Management of Locally Invasive RCC (cT4)  1.6.3
A total of 5-15% of patients present with RCC in stage T4. This stage reflects a 
tumour invasion beyond Gerotas fascia or the involvement of neighboring organs 
such as the colon, spleen, duodenum, pancreas or liver [186]. These tumors are often 
aggressive, with high-grade or sarcomatoid features. Two-thirds have N+ and/or M+ 
disease. Surgery for this is associated with a higher morbidity and mortality, and even 
unresectable disease. Unfortunately, it is often difficult to identify the invasiveness 
preoperatively [186, 187].   
Hence, a T4 tumor necessitates a multidisciplinary assessment before treatment.  
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CSS for T4 is 37 months and 8 months for non-metastatic and metastatic tumors, 
respectively. The disease often recurs despite negative surgical margins. An 
incomplete resection or debulking (kidney with adjacent organs) is also rarely 
indicated, with a positive surgical margin predicting a worse prognosis [188]. Some 
report a positive effect of renal bed radiotherapy  postoperatively [189], but trials are 
needed to evaluate its usefulness [190]. 
 Adrenalectomy  1.6.4
Ipsilateral adrenalectomy does not improve survival, Thus, today it is not routinely 
recommended for RN or PN [70, 191], but should be done concomitantly if 
preoperative imaging reveals pathology or is suspected intraoperatively [192, 193]. 
The incidence of ipsilateral synchronous adrenal metastases is low (1-2%). It occurs 
usually with large, high-grade tumors with venous involvement. The primary tumor 
location is not predictive[70]. 
 Lymphadenectomy  1.6.5
Lymphadenectomy (LND) for RCC remains controversial, and is not recommended 
when there is no suspicion of lymph node disease. A study from EORTC showed 4% 
positive lymph nodes in cN0M0 patients, though with no survival benefit for 
extended LND (eLND). LND was therefore considered a staging procedure for lymph 
node metastases  [194], influencing the current trend towards less use of LND [195].   
In high-risk patients with large tumors and adverse features, there are retrospective 
studies that suggest a benefit of eLND [70, 196, 197]. The eLND includes a resection 
of the interaortocaval nodes, of which 35-40% could be involved without 
involvement of the hilar nodes [196]. 
Except for a slightly higher risk of surgical bleeding, no increase in complications by 
doing LND is documented. Nevertheless, this acceptable morbidity is based on 
limited LND. One study indicates that the rate of lymphoceles, bleeding from major 
vessel and lesions to adjacent organs may increase with eLND [197]. Consequently, 
the benefits of LND must be carefully balanced against the total complexity of 
surgery, tumor stage and patient comorbidity. 
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Current preoperative image staging (CT/MRI) is used to detect pathological nodes. 
However, solitary enlarged lymph nodes assessed pre- or intraoperatively can often 
be inflammatory. Such a finding should not rule out a radical surgery, but a LND 
should be performed [198]. 
The fraction of lymph node-positive incidence varies from 13-30 % in older studies 
[194] to 6% in more recent ones and is higher with increasing stage [196]. Lymph 
node metastases harbor a poor prognosis and survival is comparable to systemic 
metastasis, as five-year survival worsens for all stages when combined with pN+ 
disease. Prognosis worsens with more positive nodes and extra nodal growth [197]. 
The lymphatic spread in RCC is often multifocal [199], and do not follow a strict 
template. Sentinel node is not yet an option for RCC [200]. 
 Additional surgical considerations 1.6.6
 Surgical Approach to multifocal and bilateral tumors: hereditary 1.6.6.1
and sporadic 
More than one renal tumor increases the surgical complexity. The surgeon must be 
aware of AS strategies, “the 3cm–rule”, tumor enucleation, multiple PN, re-do 
surgery and complex renal reconstruction.  All these are done with the goal of 
preventing cancer dissemination and retaining maximal renal function with as few 
interventions and as low morbidity as possible. 
 Biopsies, genetic testing and MAG3 renogram must be considered as helpful tools.  
In case of bilateral tumors, surgery could be done concomitant trough a midline 
incision, knowing that the risk of complications is greater than with staged 
procedures. A staged PN reduces the risk of acute renal failure, but requires a second 
surgery. With hereditary RCC and the possible need of repeated resections in the 
same kidney, the preservation of Gerotas fascia, minimizing hilar skeletonizing and 
avoiding unnecessary suturing at the tumor base is emphasized [201, 202]. 
 Conversions from minimally invasive to open procedures 1.6.6.2
In a British publication, the conversion rate is 4% for PN. Conversions were caused 
by bowel perforation (5.9%), hemorrhage (11.8%), failure of progress (17.7%), 
difficult dissection (23.5%) and other reasons (23.5%). The reasons for the 5.5% 
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conversions for RN were adhesions (9.4%), size of tumor (12.0%), difficult 
dissection (18.8%) and hemorrhage (28.2%). The conversion rates for simple 
nephrectomy are higher (6.6%), and mainly due to (51%) difficult dissection or 
failure to progress [203]. 
 Concomitant surgery 1.6.6.3
The increased detection of RCC is paralleled by the detection of other intra-
abdominal pathology. RN combined with benign GI surgery, does not worsen the 
perioperative outcome, but acute renal failure was more frequent when combined 
with aortic surgery [204]. Synchronous GI surgery for malignant conditions had more 
complications, however not significant. Long-term survival was mostly related to GI 
malignancy. If feasible, with a moderate comorbidity, good PS and young age, 
surgery should be considered to be performed in a single setting. Alternatively, 
lesions could be treated in sequence, with the most aggressive cancer first. The ideal 
approach must be individualized [204]. 
 Complications 1.6.7
 Intraoperative complications 1.6.7.1
Intraoperative complications must be handled the moment they occur.  The most 
frequent complication is bleeding due to a vascular injury (2%) during hilar 
dissection. It is usually avulsion or tears in veins, and more seldom from the inferior 
vena cava. Malfunction of the endovascular stapler is a feared complication with 
potentially serious consequences.  
Injury to the spleen is the second most frequent reason for bleeding (1.4-8%), with 
bleeding from liver or the pancreas occurring more infrequently.  
Bowel injuries (0.8%) are usually thermal (50%) or traumatic during access (32%). 
They cause little morbidity if they are recognized and sutured intraoperatively. 
Diaphragmatic injuries (0.6%) during dissection around the upper pol should be 
sutured and drained [40, 205].The rate of intraoperative transfusion is seldom 
reported, but transfusion during stay is reported to be 8.5-9.7%[206]. 
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 Postoperative complications 1.6.7.2
Postoperative complications are deviations from the normal postoperative course, and 
ranked by Clavien-Dindo with a severity from 1-5 assessing the need for intervention 
(pharmacological treatment, transfusions and surgical intervention) [207]. 
Comorbidity is related to complications and length of stay. Patient at a high age, high 
ASA score and esCKD are more susceptible to complications [208].  Patients treated 
at high-volume hospital (HVH) experienced a lower rate of complication than 
patients treated at a low-volume hospital (LVH) [206, 209]. 
Complications rates after PN and RN are reported to be 16-26% [210-212]. Major 
complications (defined as Clavien-Dindo ≥3) are reported to be 5.4% for PN and 
3.1% for RN [203]. In part, urinary leakage after PN constituted the difference.  
The specter of complications is similar for RN and PN: respiratory, infection, 
posthemorhagic anemia, bleeding, cardiac problems and bowel problems.  
Rates of complications do not differ significantly between ORN, hand-assisted or 
pure LN [213]. Gill previously reported the need for an extra procedure (re-do) for 
LPN vs. OPN of 6.9% vs. 3.5 %, respectively [214].   
Complications rates after PN and RN are reported to be 16-26% [210-212]. Major 
complications (defined as Clavien-Dindo ≥3) are reported to be 5.4% for PN and 
3.1% for RN [203]. In part, urinary leakage after PN constituted the difference.  
A total of 80% of major complications occur in-hospital, whereas 70% of minor 
complications occur post-discharge [211]. The re-admission rate is 5.9%, highest for 
OPN and lowest for LPN [215].  Early identification of complications is essential to 
help reduce morbidity. 
Reoperations most often occurred because of bleeding bowel perforation or infection 






Perioperative mortality is regarded a quality measure of patient selection and 
treatment. It was reduced from 5% in the 1970s to an in-hospital mortality (IHM) of 
0.7-1.4% [64, 206, 210] and 30-day mortality (TDM) of 0.9-2.8% [216, 217] in 
contemporary materials. Modern figures for mortality after cytoreductive 
nephrectomy are still higher (3.2-4.2%) [216, 217].  
IHM and TDM increase with an increasing comorbidity and complications [203, 210, 
211]. Causes of death differ, but cardiac disease, infectious diseases, embolisms and 
bleeding are typically related [212, 217]. Gastrointestinal and urologic complications 
were associated with IHM [210]. As described by Cloutier, tumor stage is 
determinant of TDM. Furthermore, patients aged 70 -79 doubled, and those >80 
tripled their mortality risk compared to those younger [216].   
For thrombus above the hepatic veins, Abel reported a TDM of 5.6%, and 90-day 
mortality of 10.5% (8.7% for level 3 and 11.8% for level 4), thereby illustrating  the 
complexity of this major surgery [218]. 
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Figure 7:  Complications that can occur after renal surgery 
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In data from the UK, TDM is lower for PN than for RN (0.10 and 0.52% for PN and 
RN, respectively) [203]. Patients treated at a HVH had less risk of dying during the 
perioperative period, compared to a LVH [219]. To improve outcomes, it is important 
to avoid the “failure to rescue”. Therefore, a department must postoperatively prevent 
complications, and organize the postoperative surveillance so that complications are 
caught early and treated by a competent specialist as soon as possible [203, 210, 212, 
220]. 
 Surgical margins  1.6.8
Negative surgical margins (NSM) are among the goals of oncological surgery. 
However, positive surgical margins (PSM) are reported to occur in 0-7% with OPN, 
1-4% with LPN and 4-6% with RALPN [221, 222].  
PSM occurs more often with smaller, endophytic, complex and centrally located 
tumors, but also when multifocal, there is a lack of a tumor pseudocapsule and in PN 
performed for imperative reasons [221-223]. Adherent (toxic) perinephric fat could 
create difficulties in defining the right plan of resection.  
Contradictory results are published regarding the prognostic value of PSM. Some 
report an increased recurrence of both localized and metastatic disease [224]. 
However, Kang et al. found no significant difference between PSM and NSM 
according to recurrence after PN for T1 ccRCC [221]. Shah et al. found a higher 
recurrence in patients with high-risk and high-stage RCC with PSM [225]. Even so, 
the PSM and recurrence do not appear to influence CSS, so careful surveillance may 
be sufficient for first-line management and re-resection, and nephrectomy should 
probably remain a second option [223].   
1.7 Management of mRCC 
 Metastatic pattern in RCC  1.7.1
Synchronous RCC metastasis occurs in 20-30% with a falling incidence [226]. 
Another  20-30% with primarily localized RCC will develop metastasis, of these, 
50% will recur within two years and 75-80% within five years [227]. After 10 years 
of a disease-free interval approximately 10% of those still at risk will experience 
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metastases. Metastasis most frequently occurs in the lungs, and are mostly multiple. 
The route of pulmonary metastatic RCC is hematogenous through the renal sinus, 
renal veins and vena cava, leading to pulmonary metastases.  
Drainage through the lumbar veins facilitates the spread to the low-pressure superior 
and inferior paravertebral venous plexus and to lumbar and pelvic veins, generating 
metastasis in the CNS, the head and in the central- and peripheral bone.  
Nodal involvement could be located in the hilar, aortic, caval, thoracic duct and 
thoracic nodes, with these different pathways resulting in a spreading to unusual sites. 
The primary renal tumor and their metastases can differ in biological characteristics, 
and changes in gene-expression influence RCC aggressiveness. Early metastasis, i.e. 
< 9 months after nephrectomy, have a worse outcome than late metastasis (> 5 years) 
[228]. 
 Nephrectomy in patients with mRCC 1.7.2
Historically, two randomized studies [229, 230] showed an improved OS for 
cytoreductive nephrectomy and interferon over interferon alone. Combined, these two 
studies showed an improved OS of 6 months, 13.6 vs. 7.8 months for CN, followed 
by IFN vs. IFN alone [231]; favorable patients experienced the best results from this 
combination.  
With the introduction of targeted therapy (TT) for mRCC, most patients in the early 
studies were nephrectomized. Several retrospective studies have shown a survival 
benefit of the combination of CN and TT over TT alone [232, 233].  
Two prospective randomized studies have investigated the effect of CN in 
conjunction with TT. The CARMENA study was recently published, and revealed no 
difference in OS for CN+Sunitinib and Sunitinib alone [234]. However, the study has 
been criticized due to patient selection, and thus general validity. Nonetheless, the 
study demonstrates that for patients with intermediate and poor-risk disease, and a 
high metastatic tumor burden, upfront CN does not seem indicated. The other study, 
the SURTIME-study [235] showed an improved OS after deferred CN over 
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immediate CN. Unfortunately, the SURTIME study is severely underpowered, so 
conclusions are therefore difficult to draw.  
After these studies, CN is still a valid treatment option for carefully selected mRCC 
patients. For patients with a low metastatic burden and time point, the start of 
systemic therapy might be awaited. It is reasonable to presume that international 
guidelines will be updated within a short period of, hence reflecting the results from 
CARMENA and SURTIME.  
Morbidity and mortality rates after CN are not negligible, and a thorough 
preoperative risk evaluation is essential to help reduce this. Perioperative mortality is 
higher for CN than RN, 2.4% vs. 0.6-0.9% [203, 209, 216]. A failure to rescue occurs 
more frequently in patients aged > 75 with postoperative infections, cardiac-, 
pulmonary or vascular problems [236]. Predictors of postoperative morbidity are also 
pathological lymph nodes, liver metastasis and the need of intra-operative blood 
transfusions.  
Unaffected by the newer studies, CN is still an option to palliate symptoms (bleeding, 
pain, paraneoplastic manifestations, etc.). Even so, the number of such patients are 
limited, and is infrequently done because the symptoms can be treated without 
surgery and hematuria managed by angio-embolization. 
Reports on nephrectomy, combined with a complete resection of metastasis (single or 
oligometastastic RCC), that could be curative are few, but do exist. Removal of the 
primary tumor may restore immune competence in the mRCC, and the temporary 
regression of metastasis after CN is also observed [237]. 
 Management of RCC metastases  1.7.3
Studies on metastasectomy are retrospective and comparative, and no randomized 
studies exist. It is difficult to demonstrate a favorable outcome since reports on 
metastases to various organs are very heterogeneous. Surgery is often mixed with 
systemic and/or radiotherapy.  
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An OS of 41 months is reported for a complete resection of limited metastasis, and 
the OS is longer for complete than incomplete resections[70]. If a complete resection 
is possible  and patient in good performance status (i.e. single or oligometastases to 
the lungs), a resection or lobectomy are the most used options, but ablative 
techniques are also reported[238].  
 Surgical resection should be considered if possible for bony metastasis causing pain. 
Surgery is important to stabilize pathological fractures (i.e. the femur or humerus) or 
treat medullary- or root compression by metastases in vertebrae. The latter is often 
combined with adjuvant radiotherapy; otherwise, stereotactic radiotherapy is an 
alternative [70]. Patients with brain metastasis will benefit from stereotactic 
radiotherapy, and especially if solitary. It could also be combined with surgery or 
whole brain radiation [70]. 
 Management of locoregional recurrence  1.7.4
Locoregional recurrences after PN, AT and RN include intrarenal and perirenal 
relapse. The most effective salvage procedure is not yet defined, but repeated AT or 
new surgery is advocated for intrarenal recurrence if possible.   Most common are 
locoregional recurrences in the renal vein or fossa, or in lymph nodes and adrenals. A 
short time to relapse, a large size, sarcomatoid features and positive margins after re-
surgery negatively influence the prognosis. If feasible, surgical removal can impact 
local control and survival [70, 239]. Systemic therapy or stereotactic irradiation 
should also be considered when surgery is impossible. 
 Systemic treatment in mRCC  1.7.5
Systemic therapy works through various mechanisms of actions to hamper tumor 
growth. Many new agents are introduced at a high speed and the field is rapidly 
changing. Current challenges are when to initiate, switch and discontinue, and how to 
sequence treatment. These decisions are affected by patient performance status and 
tolerance, symptoms from the disease, imaging and drug availability.  The guidelines 
differentiate between preferred drugs recommended for first-line and subsequent 
treatment lines, stratified for prognostic groups (IMDC or MSKCC). Systemic 
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therapy is not a primary focus of this thesis. So in the following, the different 
treatment options are briefly discussed with the recommendations mentioned 
reflecting the standard of care as of June 2018.   
 Immunotherapy 1.7.5.1
The spontaneous regression of metastases after nephrectomy was the earliest 
evidence that the immune-system was involved in RCC. The response was infrequent 
(1%)  and often transient mediated by T- and B-lymphocytes [40] but stimulated to 
the development of immunotherapeutic approaches.  
The cytokines interferon-α (IF-α) and interleukin-2 (IL-2) are immune-modulating 
proteins [240]. IF-α had response rates of 16-26%, and OS 8.5 months, this would be 
2.5 months longer than for medroxy-progesterone [241]. The associated toxicity was 
severe for high-dose IL-2.  The response rate was 15-20% and 7% of responders 
exhibited a complete response, of which 60% were without recurrence at FU [242].  
Allogenic Hematopoietic Stem Cell Transplantation and vaccine therapy are 
considered experimental [40].  
The newest set-up for immunotherapy is 
the immune checkpoint inhibitors and 
show promising results in regard to 
progression free survival (PFS), OS and 
side-effects. They are human monoclonal 
antibodies towards receptor involved in 
tumor suppression, and intend to 
upregulate the immune response. 
Nivolumab inhibits the programmed death 
ligand 1(PD-L1) receptor expressed on 
macrophages, T- and B-cells. Ipilimumab 
is an inhibitor of antigen 4-receptor 
(CTLA-4) expressed on cytotoxic T-
cell[40, 70].   
Figure 8: Inactivated VHL protein results in HIF accumulation and 
up-regulation of growth factors. When secreted they bind to tyrosin-
kinase receptors on the surface of endothelial cells and vascular 




 Targeted therapy  1.7.5.1
In ccRCC, hypoxia-inducible factor (HIF) accumulates due to VHL inactivation, and 
results in an overexpression of vascular endothelial growth factor (VEGF) and 
platelet-derived growth factor (PDGF), which in turn promotes angiogenesis. The 
function of VHL protein has identified targets for therapy. Targeted therapy (TT) 
includes the tyrosine-kinase inhibitors (TKI), monoclonal VEGF antibodies and the 
mammalian target of rapamycin (mTOR). 
TKIs inhibit principally the VEGF receptor (VEGFR) and the PDGF receptor 
(PDGFR) with both anti-tumor and anti-angiogenic activity. Sunitinib was used as 
treatment from 2006/2009 and demonstrated a partial response rate of 30-40% with 
PFS and OS of 5-6 mo longer than cytokines [243, 244]. It is the most widely used 
oral TKI in mRCC. Other established TKIs are sorafenib, axitinib, pazopanib and 
cabozantibib, the two latter demonstrating less side-effects [40]. Newer TKIs include 
levantinib and tivozantinib are still under evaluation. 
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Figure 9:  EAU guidelines 2018 for the systemic treatment of metastatic clear-cell renal cell carcinoma.  
*pazopanib for intermediate risk only 
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first-line TKI alone or combined with IF-α[70]. mTOR is an intracellular protein 
important in signal cascades for growth factors, and blocks HIF translation. The 
mTOR inhibitors temsirolimus and everolimus  is recommended for second-line 
therapy [245]. 
 Chemotherapy 1.7.5.2
RCC is considered chemo-resistant, and approaches with 5-FU, platinum compounds 
and vinblastine have been disappointing. The combination of gemcitabine with 
doxorubicin or TKIs could be an option for sarcomatoid RCC [40, 70, 246].  
 Aspects of metastatic non-CCRCC 1.7.5.3
The recommendation applies for mccRCC, and for the time being there is no standard 
approach or proven efficacy metastatic non-ccRCC [126]. There is a lower response 
rate in pRCC to TKIs probably because they do not harbor the VHL-mutation. 
Collecting duct carcinoma is treated with gemcitabine and carboplatin with modest 
effect. 
1.8 Survival 
Figure 10 illustrates updated Norwegians numbers on relative survival. For localized 
disease, there is a 5-year RS approaching 90% compared to the mid-1990s, when it 
was just below 80%. In comparison with the older Robson publication from 1969, the 
5-year survival for localized disease (Robson stage I = T1 and T2) was 66%.For 
advanced and metastatic disease, the numbers also show improvement over the last 
few decades [14].  
5–year Relative Survival by stage, gender and period of KC-diagnosis in Norway [14] 
Stage 1982-86 1992-96 2002-06 2007-11 2012-16 
Total 44.8 41.7 52.9  52.0 63.1 60.3 71.6 66.6 74.8 73.7 
Localized 70.0  71.4 76.6  76.9 86.7 85.0 89.0 86.8 90.0 89.6 
Regional 49.3 44.2 51.6 53.0 48.9 54.3 47.7 58.6 51.3 63.7 
Distant   7.2   6.8 2.8    6.2 11.1   8.8 16.4 9.3 11.4 10.5 
Unknown  - 41.3 33.4 63.6  68.8 80.6 70.0 51.6  43.7 
Figure 10: RS presented in % by stage and period of diagnosis. Females in black and men in blue. 
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CSS is illustrated in figure 11. For pT3a tumors CSS differs according to the type of 
perirenal invasion. Only renal vein invasion, only perirenal fat invasion and a 
combination shows a 75%, 66.9% and 32.4% 5-year CSS, respectively. Similarly, for 
pT3b tumors the CSS was 36% with concomitant perirenal invasion, but reached 
65.9% without.  To have nodal disease double the CSM, and for patients with 
metastatic disease, the CSM was four times higher than without metastasis [247].  
ccRCC presents with advanced disease (T3-4, N+, M+) at 28% compared to 17% in 
pRCC and chRCC, with the latter two demonstrating a better long-term survival 
[248]. 
Renal Cell Carcinoma 5-year Cancer Specific Survival  
Stage T1a T1b T2a T2b T3a T3b T3c T4 
5-yr 
CSS 
94.9 92.6 85.4 70 64.7 54.7 17.9 27.1 
Figure 11: Cancer specific survival for RCC in % , adapted from Novara 2009 [247] 
1.9 Follow-up(FU) for RCC  
The focus of the present thesis is on treatment, so therefore FU is only summarized. 
Follow up programs (FUP) after PN or RN should identify surgery-related 
complications, follow renal function and detect recurrence or metastasis. Different 
FUP exists [70, 249, 250], but there is no consensus or high-level evidence on the 
optimal FUP or its duration. In general, there is very little high-level evidence for 
recommendations given for follow-up in RCC.  
It should be individualized and risk-stratified [70], and patients experience better 
survival within FUP than without [250]. Most FUP is limited to five years when the 
risk of recurrence is highest [227, 250]. Guidelines recommend subsequent imaging 
control biannually for intermediate- and high-risk groups (UISS risk stratification) 
[70]. Clinical examination, blood samples and chest imaging plus a CT/MRI of the 
abdomen constitute the usual FUP visit [227, 250]. 
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Postoperative scoring systems and nomograms aim to discriminate risk groups and 
predict recurrence and survival. They integrate clinical information, in addition to the 
histopathology.  Stratifying patients postoperatively into low-, intermediate- and 
high-risk groups for recurrence is done with the Leibovich risk model and the UCLA 
Integrated Staging System (UISS) [61, 251]. Leibovich included pT, pN, tumor size > 
10 cm, Fuhrman grade and necrosis, while Zisman restricted it to pT, Fuhrman grade 
and ECOG-PS. Another validated prognostic algorithm, the SSIGN, predicts survival 
and defines five risk groups [60]. Nomograms such as Kattan, Sorbellini and 
Karakiewich sum different weighted factors to predict the probability of 5-y RFS, 
CSS and OS [252-254]. One is also made for PRCC, while most of the others are 
constructed for ccRCC [255]. Surgeons can better counsel patients postoperatively by 
using these and designing follow-up programs FUP suitable to detect treatable 
recurrences in time. The intermediate- and high-risk groups need a more intensified 
FUP, with more frequent imaging than the low-risk group. In case of recurrence or 
metastasis, survival may be improved in suitable candidates for systemic therapy, 










2. Aims of the Thesis 
General aims 
The major aim of this thesis was to explore whole nation data, reveal trends and 
obtain updated numbers on KC treatment in the six-year-period from 2008-2013. To 
the best of our knowledge, this is the first register study on KC in Norway to such an 
extent. Both in the years before and during the study period, the field of KC 
management has undergone substantial changes. The new guidelines supported the 
implementation of nephron sparing and laparoscopic surgery. In addition, active 
surveillance and ablative treatment were emerging methods. Furthermore, the use of 
pre-diagnostic biopsies for tailoring treatment was introduced. Since the Norwegian 
government set hospital volume requirements for hospitals to do KC surgery, we 
could also investigate hospital volume vs. patient outcomes in our cohort. 
Paper I 
The purpose was to describe the use of diagnostic biopsies for localized and mRCC in 
a population-based setting, and to evaluate whether the practice patterns were in line 
with updated guidelines. We looked for predictors for performance of RMB, and if 
doing RMB influenced treatment. 
Paper II 
The aim was to investigate whether Norwegian surgeons implemented MIM and PN 
according to changes in European guidelines. Analyses of national and regional 
trends and patterns in KC surgery were performed. Lastly, outcome in terms of 
survival was studied.  
Paper III 
Norwegian health authorities introduced new requirements for hospitals to continue 
to perform KC-surgery, acknowledging that surgical volume was most likely 
associated with improved patient outcomes. We wanted to establish Norwegian data 
on outcome, and compare the impact of hospital volume on outcome in regard to 
TDM following KC surgery 
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3. Material and Methods 
3.1 Permissions and ethical considerations  
Since 1953, Norwegian clinicians and pathologists have been requested by law to 
report all new cases of cancer to the population-based Cancer Registry of Norway 
(CRN). The CRN is further connected to the Norwegian Population Registry (NPR). 
Information about all types of patient/doctor contacts is transferred from the national 
public health-care system to the CRN. Inclusion in the CRN is mandatory, which is in 
accordance with national regulations; as insofar present study did not need informed 
consent from the patients when data was gathered at the CRN. 
3.2 Data extraction from the Cancer Registry of Norway 
At the CRN, datasets from 4,465 KC patients (ICD-10 code C64) diagnosed during 
the six-year period from 2008-2013 were extracted from the primary database (figure 
12). The datasets consist of demographic, tumor-related-, treatment-related- and 
follow-up-related variables. Different subsets of data were used for the three different 
articles, as illustrated in the flowchart. At the CRN, all entered data was manually 
assured from the registry source. 
During this process, 16 patients were excluded due to an improper diagnosis, and the 
datasets for 4,449 patients were transferred to an anonymous database for subsequent 
analyses. All patients were restaged according to the TNM 2009 edition based on 
reading histopathology reports, clinical reports, irradiation reports, surgical records 
and diagnoses and procedures noted at discharge. Data on survival was obtained from 
the CRN (Paper I, 30 June 2016; Paper II, 31 Dec. 2016; Paper III, 31 Dec. 2014).  
3.3 Study population 
Paper I: From the anonymous dataset of 4,449 patients, patients <18 year, with a 
lack of biopsy data and date of diagnosis < 30 days prior to death or autopsy, were 
excluded and the final study population consisted of 4,051  
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Figure 12: Flowchart illustrating the different studypopulations 
Paper II: From the anonymous dataset of 4,449 patients, patients ≥18 years, N0 M0, 
KC≤7 cm and treated with RN or PN were included in the final study population, a 
total of 2,420 patients remained.  
Paper III: A subset of data for hospital stay and surgical conversions was available 
and consisted of all patients for 2010-2013, but data were missing in part from the 
two first years. A total of 3,313 patients ≥18 year, treated with PN or RN, remained 
in the dataset. Hospitals performing less than four KC surgeries during these six years 
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were excluded (average of ≤0.5/year). The final study population consisted of 3,273 
patients.   
3.4 Statistical analysis 
Standard descriptive statistics: Mean values are presented as Mean ± standard error of 
means (SEM). Median and interquartile range (IQR) is used for descriptions of 
variation within groups. 
T-test: Comparison of continuous variables, normally distributed. 
Mann-Whitney U-test: Comparison of continuous variables, non-normally 
distributed. 
Exact chi–square test (χ2): To determine the significant level of difference for 
categorical data. A p–value < 0.05 was considered statistically significant. 
Bootstrapping: 1,000 resamples for TDM rates with associated confidence intervals 
(CIs) are used in Paper III because the proportion of TDM I is low (simulate TDM 
rates for 1,000 cohorts of 3,273 patients, i.e., 3,273,000 patients). 
 
Cox proportional regression: Multivariate analysis. 
Kaplan-Meier method: A survival analysis/survival plot of incomplete observations 
and Log-Rank test were used to determine statistical significance between groups.  
 
Overall survival (OS): Time from diagnosis or surgery to death irrespective of cause. 
Cancer Specific Survival (CSS): Time from diagnosis or surgery to death from 
cancer. 
Relative survival: Calculated by the method of Pohar-Perme [258]. 
Competing risks assessment: Conditional probability estimates for different groups.  
 
Multiple logistic regression models: Established without pre-selections of variables 
(Papers II, III). 
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Joinpoint Regression Analysis: Calculated using Joinpoint Regression Program, 
Version 4.5.0.1- June 2017, Statistical Methodology and Applications Branch, 
Surveillance Research Program, National Cancer Institute. 
Calculations:  Performed using IBM SPSS Statistics software (Release 23.0 and 24.0; 
IBM Corp., Armonk, NY, USA) or R software (R –version 3.3.0; the R foundation 
for Statistical Computing, http://www.r-project.org/) with the survival packages, rms 
and cmprsk. 
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4. Summary of Results  
4.1 Paper I 
A diagnostic biopsy was performed in 20.2% of the patients, with a small increase 
between the first and second part of the study period, 19.7% vs. 20.7%.  
For patients with localized RCC, we found a significant increase in the use of 
diagnostic biopsies from 9.1% to 11.5%, which was partly driven by a doubling of 
RMB among patients for observation. The use of RMB was more frequent in older (> 
70 years) than younger patients (< 70 years), in tumors ≤ 4 cm than 4.1 ≤ 7 cm and in 
patients with a secondary primary cancer (for all; p < 0.001). Age, size, multiple 
tumors and secondary primary cancer were all predictors for RMB in a multivariate 
logistic regression model. Patient managed by observation were older, with more 
other primary cancers and more RMB than actively treated patients (for all; p < 
0.001). There was a tendency towards a lower Fuhrman grade in tumors in the 
observation group (81% vs. 68%).Of patients with N1M0 disease (54), 72% received 
active radical treatment, but only eight of the 54 patients underwent RMB. For M1 
patients, there was a close to significant increase in RMB. Fewer patients with mRCC 
were without histopathology verification in the second period, 19% vs. 14%. Those 
without histopathology had significantly poorer survival than those with RMB. The 
majority of biopsies were performed in patients who had CN. The use of CN was 
stable in the study period, performed in 35% of patients with metastatic kidney 
cancer. 
4.2 Paper II 
Patients undergoing RN were older (64.8 yr vs. 61.2 yr) with larger tumors (4.3 ± 0.4 
vs. 2.7± 0.4) than PN patients.  
There was a 28% increase in surgical treated patients with tumors ≤7cm. While the 
number of RN annually was stable, the use of PN doubled. 
Joinpoint analysis illustrates an increased use of PN and a decreased use of RN. In the 
entire study period, 58% of tumors ≤4cm were treated with PN. A significant 
increase in PN was registered from 2008 to 2013 (43% vs. 66%).For tumors 4.1 - 7 
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cm, only 14% underwent PN, but increased from 10% to 18% (2008-13). MIM 
showed an increase for both RN and PN. MIM-RN rose from 53% to 72% and MIM-
PN from 25% to 64%, of which 55% was RALPN in 2013. Distribution of PN and 
RN, Open- and MIM procedures differed significantly between counties and regions, 
but throughout the period an increase of both PN and MIM was seen.  
 
 
Figure 13:  Distribution of treatment in the four Regional Health Authorities for ORN, MIM-RN, OPN 
and MIM-PN. Minimally Invasive includes pure laparoscopic, hand-assisted and robot-assisted method. 
 
 
In multivariate logistic regression, younger age, smaller tumor size, HVH, second 
half of the study period and Western (WHA) and Central Health Authority (CHA) 
remained independent predictors of PN. Predictors for MIM were female gender, 
HVH, second half of the study and South-Eastern Health Authority (SHA). 
A Kaplan Meier Plot illustrates an overall survival benefit for patients undergoing PN 
or RN. In a Cox regression analysis, PN, age, Fuhrman grade and stage were 
predictors of survival, and no difference in CSS was found (p =0.8). A 5-yr relative 
survival was higher for PN than RN, though not significant for both T1a 98.1 (95% 
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CI 93.6-99.4) vs. 92.8 (95% CI 88.1-95.7) and for T1b: 98.8 (95%CI 16.3-100.0) vs. 
90.0 (95% CI 85.1-93.3).   
Competing risk analysis revealed a higher probability of competing risk in the RN 
group compared to the PN group, with an early separation of the curves. When 
splitting other causes of death into cancer and non-cancerous conditions, PN and RN 
had the same probability of death from non-cancerous conditions the first two years 
before the curves separate and the competing risk increased for RN.  
4.3 Paper III 
Of the 3,313 who had surgery done for KC from 2008-2013, 69% underwent RN and 
31% underwent PN; almost the same proportion did open and MIM procedures.   
Twenty-nine patients died within 30 days, while the overall mortality rate was 0.89%. 
TDM for localized and metastatic RCC was 0.73% and 2.6%, respectively.  
For all stages, TDM was higher in older age groups, and significantly lower for PN 
and MIM procedures. On average, low-volume hospitals did 5.2 procedures/year, 
intermediate-volume hospitals did 27/year and high-volume hospitals did 53/year; the 
overall TDM for these hospitals was 2.2%, 0.83% and 0.39%, respectively, 
(p<0.001). In the multivariate logistic regression model, hospital volume, tumor stage 
and age were independent predictors of TDM following KC surgery. The odds ratio 
(OR) for TDM in the LVH compared to the HVH was 4.98 (CI 1.72-14.4) for patients 
with distant metastasis (p =0.003), and 3.35 (CI 1.32- 8.50) for patients with p T1-2 







5.1 Pretreatment evaluation 
In Paper I, we explore how many diagnosed patients who had a biopsy before the 
choice of treatment was taken. This was possible if the biopsy was confirmed, such as 
KC/RCC on histopathology. The complete use of RMB was not possible to reveal 
because benign and non-diagnostic biopsies are not reported to the CRN, but others 
have reported it to be approximately 26% and 10-20%, respectively[131, 134]. We do 
not know the numbers of re-biopsies, nor the numbers of cores needed to verify 
malignancy. Additional RMB showing non-renal malignancy was not accessible for 
us. The diagnostic yield is reported to be lower with small, endophytic and cystic 
lesions, and in biopsies of tumors with a complex location [131-133]. In this way, the 
biopsy rate may be influenced by location, size, as well as patient anatomy, adipositas 
and radiologist experience. However, this study pictures the magnitude of RMB pre-
diagnostic, and how information from malign biopsies is used in a treatment setting. 
In the European Association of Urology (EAU) guidelines from 2009, RMB is only 
mentioned in one line: “There is a limited indication for fine needle biopsy.” In 2010, 
the importance of RMB was more emphasized and given its own chapter. Based on 
new publications and evidence, it was stated that biopsy always should be done 
before ablative therapy and systemic therapy (without previous histopathology), and 
is recommended in surveillance strategies. 2010 was also the first year that 
surveillance and ablative treatment were noted as alternative treatments. An increased 
use of RMBs was noted before, but when documented in guidelines surgeons realize 
both the role of RMB and surveillance as options. The use of biopsies is a part of the 
modern more tailored and customized treatment.  
We found that 20.2% of diagnosed KC patients had RMB, and it was used as a pre-
diagnostic tool for surveillance, in active treatment for localized disease and in a 
metastatic setting, both for those who underwent CN and not. Because the literature is 
sparse and there is a lack of comparable data on the real-life use of RMB, our rate of 
use is difficult to interpret. The use of RMB for localized KC increased significantly 
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from the first to second period, from 9.1-11.5%. Of those treated with surgery, 8.4% 
had pretreatment RMB with a slight but not significant increase. For localized KC 
managed with observation, the rate of RMB was doubled from 29% to 61%, which 
illustrates an increased rate of patients when a verified malign biopsy was scheduled 
for surveillance. Patients undergoing observation had a tendency towards a low 
grade, compared to those undergoing active treatment. Hopefully, this illustrates that 
several more tumors in general were biopsied, and that those found to be benign did 
not undergo surgery and were spared from unnecessary follow-up.  
Only seven patients underwent ablative treatment, and all had pretreatment RMB as 
is in line with recommendations.  
The increase in use of RMB for localized KC reflects the growing awareness of an 
increasing incidence of SRM in general and in the elderly [15], and probably a more 
active trend of going for active surveillance. In a study from the Nordic countries, 
Nisen reported that 11%, 26% and 30% of resected renal tumors ≤ 4 cm were benign 
in  Denmark, Norway and Sweden, respectively [259]. This illustrates that both 
biopsy and treatment practice may vary in these neighboring countries. The 
occurrence of 30% benignity in resected SRM is also seen in published materials 
from the USA [133]. 
Indication for biopsy is discussed in several papers and as expected, predictors for 
biopsy for localized cancer in our study were small tumor, secondary primary cancer, 
multiple tumors, older age and second period. This use of RMB reflects that the 
urologists can perform a risk-to-benefit analysis to construct a surveillance or surgical 
plan for the patients. Because age can be used as a proxy for comorbidity [216], this 
probably illustrates that patients with limited life expectancies could be sorted for 
surveillance. 
Fewer metastatic patients in the second than in the first period were without verified 
histopathology, 19% vs. 14%, respectively. RMB was not performed for almost half 
the patients >80 years, compared to 14.5% of patients between 70-79 years and 3.1% 
< 60 years. This illustrates that many of the oldest were likely not candidates for 
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either surgical or systemic treatment, unlike the approach in young metastatic 
patients. 
Approximately 80% of the patients with localized disease did not have any biopsy 
and 90% of these underwent surgery, which could be considered to be in line with 
current guidelines; patient scheduled for surgery do not need biopsy.  
From initially only being indicated in patients with other primary malignancies, 
solitary kidneys, older age and severe cardiac or pulmonary comorbid conditions 
[127], RMB is now an important instrument in pre-treatment evaluation, and its 
importance will probably increase patient candidates for a surveillance strategy [70]. 
Because of the earlier perception that the biopsy would not change treatment, the fear 
of false-negative biopsies may be the reason why many urologists do not use 
pretreatment RMB, as illustrated in two surveys [260, 261]. In a review, RMB is 
shown to impact management in 24-64%. Benign histopathology is described to avert 
surgery in 16-26% [131-133]. The diagnostic accuracy of RMB has improved. A 
recent meta-analysis illustrates the ability to differentiate benign from malign lesions 
(81-97%), to determine subtype (86-98%) and also that the concordance with the 
final specimen is good [133, 136]. Based on this, urologists will probably trust RMB 
more and in the future actively use the results in management decisions. Current 
Norwegian biopsy patterns seem to be in line with recommendations in the 
guidelines. 
5.2 Treatment 
5.2.1 New evidence - changes in guidelines   
In Paper II we focus on N0M0 patients, who were surgically treated for tumor size ≤ 
7 cm. Today, surgeons choose PN if feasible for tumors of this size, and secondary 
RN [70]. In 2008, the scenario was quite different. From 2006, the EAU Guidelines 
implemented PN as care for tumors ≤ 4 cm, and for tumors 4.1-7 cm was the only 
option for selected patients at experienced centers [262]. Guidelines changed 
significantly in 2010, when PN became standard care whenever feasible for all 
tumors ≤ 7cm. Moreover, LRN was recommended for cT1 if PN was not possible 
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[144]. By using the dataset from the CRN 2008-2013, we wanted to find out how 
these expanded indications were adapted among Norwegian urologists, and how 
practice patterns were influenced by guidelines. 
5.2.2 Distribution of treatments  
In Paper II, we clearly demonstrate that the overall use of PN in Norway increases 
from 31% to 49%, and the increase is greatest for tumors ≤4 cm from 43% to 66%, 
but also substantial for tumors 4.1–7 cm from 10% to 18%. This is in line with 
current evidence-based knowledge for localized KC ≤7 cm, which advocates PN 
rather than RN whenever feasible. Norwegian data is comparable to Dutch, Swedish 
and data from other continents [18, 263, 264]. In the Dutch study (2010-2014), Aben 
found the amount of PN in 2014 was 67% for T1a and 30% for T1b. Ljungberg 
demonstrated an increase in PN for cT1a from 22% to 53% from 2005-2011, with a 
higher rate of 9% AT in Sweden vs. 5% AT in The Netherlands. Likewise, he found 
an increase from 0% to 10% for T1b. USA data from the period just before 2008 also 
illustrates this gradual increase in the use of PN [265]. 
Simultaneously, the use of laparoscopic procedures increased, a trend seen both for 
RN from 52% to 72%, and for PN from 25% to 64%. A clear treatment shift is seen 
in 2010, reinforced by new guidelines and publications. Surgeons were reassured 
with the knowledge of the oncological equivalent of PN and RN for tumors ≤ 7 cm, 
and could be performed if feasible [127, 144, 266]. Secondly MIM-RN and MIM-PN 
were equitable to the open procedures [127, 144, 214], and LRN should be done if 
PN was not possible. The rate of complications for both open and MIM surgery were 
comparable. The documented lower perioperative morbidity, better cosmetics and 
QoL were advantages that made MIM preferable over open surgery [71], both for 
surgeons and patients. Referral routines could be influenced when patients demanded 
a laparoscopic procedure, if his or her primary hospital could not offer this. 
Additionally Go’s publication from 2004 illustrated a dose-dependent risk of death 
from any cause, cardiovascular disease and events and risk of hospitalization related 
to CKD [75]. RN was found to be a significant risk factor for developing CKD, 
compared to PN for small renal cortical tumors [267].The importance of renal 
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preservation on OS and morbidity was assumed; however, controversies exist and 
further investigation of this association has been and will be crucial [78, 79].  
The pure laparoscopic PN is more challenging than laparoscopic RN. The 
intracorporal suturing in LPN is perceived by urologists to be technically difficult and 
time-consuming, which may have limited the implementation. The initial experience 
with robot-assisted laparoscopic partial nephrectomy (RALPN) was encouraging 
[143]. The three-dimensional visual field and magnification made the procedure safer 
and easier. The robotic platform and RALPN is later shown to increase the adoption 
of PN, probably because of a shorter learning curve than LPN [147], with favorable 
results concerning complications, conversions and ischemia time [268]. In Norway, 
the robotic platform was acquired in SHA in 2004, in WHA in 2009, in CHA in 2010 
and in Northern Health Autorithy (NHA) in 2012, with the first kidney surgery done 
in 2006, 2010, 2010 and 2012, respectively, (information from Intuitive). Since then, 
acquisition of the robotic platform in Norway has continued, and today 15 robotic 
systems are distributed in Norway. In our cohort, the use of RALPN surpassed pure 
laparoscopic PN in 2013, which both illustrates the feasibility and increased 
availability of the robotic platform. Improvements are also done in standard 
laparoscopy, by offering the 3-D laparoscopy. For RN, this is surely better, and could 
probably increase the use of PN as well. 
Paper III illustrates the distribution of all surgical management for KC during the 
study period. A total of 74.4% of patients >18 years underwent surgery, and of these 
69% underwent RN and 31% PN. LVH performed significantly less PN and MIM 
procedures than intermediate-volume hospital and HVH, thereby illustrating a slower 
adherence to guidelines and the implementation of new procedures. 
5.2.3 Cytoreductive nephrectomy 
In Paper I, we found that 35% of patients diagnosed with metastatic RCC underwent 
CN, with no difference from the first to second period, which is lower than in Sweden 
where the number for CN was 58.5% for 2009-2012 [269]. The majority of biopsies 
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were performed in patients who did not undergo CN, many probably heading for 
systemic treatment, though this data was not accessible.  
5.2.4 Regional differences in treatment 
Interestingly, in Paper II we found pronounced discrepancies in treatment between 
the four HA. We revealed that RN was used more regularly for patients within the 
SHA and NHA compared to the CHA and WHA: 62% and 63% vs. 55% and 45%, 
respectively. Furthermore, the most frequent procedure in SHA was LRN, as was 
OPN in the WHA. Earlier studies have suggested a possible negative impact of LRN 
on the use of PN, and surgeons were doing urologic laparoscopy on small renal 
tumors to achieve that experience. In the publication from Australia, when LRN was 
introduced the rate of PN fell, but rose again after some years [270]. Norwegian data 
on the distribution of treatment before 2008 is not available, although the Norwegian 
situation could be similar. It is also shown that the use of the robot facilitates more 
PN in general and not only RALPN [271].  
Another theory is that different surgical traditions and practice settings were decisive. 
PN was more frequent among younger surgeons in university hospitals, increasing 
renal case volume and the percentage of PN [18, 272]. Predictors of doing MIM were 
also younger surgeons and high surgeon volumes [273]. The characterization of 
surgeon level on the uptake of contemporary treatment is not well understood, and 
many factors are probably involved. The understanding of feasibility differs and 
correlates to the surgeon’s skill and experiences. 
Patients living within one HA experienced a divergent treatment strategy, but trends 
toward a more equal distributed treatment for the second period. For all counties, an 
increased use of PN was documented. Corresponding variability is seen in 
population-based data from Sweden [18]. A different referral practice could also 
influence this diversity. 
Hospital volume is also discussed in several publications, and will influence the type 
of surgery, perioperative complications, morbidity and mortality. In our study, we 
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demonstrate in both Papers II and III that PN and MIM procedures were done 
significantly more at HVH. 
5.3 Survival  
5.3.1 Short-term survival for surgically treated patients 
Perioperative mortality is considered a major indicator for the quality of patient 
outcomes, which is focused on in Paper III. Perioperative mortality summarizes 
patient selection, surgical treatment and postoperative care. At least two definitions 
for this are in use, the TDM and IHM. Literature reports this to be approximately 0.-
1.5% for localized KC and 2-4% for metastatic KC.  Most authors use IHM, but this 
is often lower than TDM. Unlike IHM, TDM illustrates mortality independently of 
length of stay, discharge- and readmission routine and geography. Bilimoria et al. 
demonstrated that 39.7% of postoperative complications and 23.6% of deaths 
occurred post-discharge [274], and that TDM was a more reasonable measure than 
IHM. The TDM of 0.89% we found in our study is comparable to other data of the 
time [216]. Well-known determinants of TDM, such as patient age, stage and  
metastatic disease, were also found  to be predictors of mortality in our cohort [216], 
the latter illustrated with 0.73% for TDM for localized- and 2.6% for metastatic 
disease.  
A striking finding was the relationship between hospital volume and TDM. In many 
other malign and benign diseases, HVH are associated with improved patient 
outcomes. The Norwegian government relied on this data when new volume demands 
for hospitals doing KC surgery were put on top of the general requirements. The 
definition of LVH and HVH vary in the literature and hospital volume definition used 
in our study is based on KC surgery requirements declared from Norwegian 
government. LVH, IVH and HVH presented significant differences in TDM for all 
stages of 2.2%, 0.8% and 0.4%, respectively. Regarding metastatic disease and 
cytoreductive nephrectomy, the difference was greater, 5.0% for LVH and 2.2% for 
IVH and HVH. Our primary hypothesis was that no difference existed, although this 
was disproven.   
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This hospital level variability in outcomes is multifaceted. There is an increasing 
attention towards measuring and reducing postoperative morbidity. Postoperative 
mortality is related to postoperative complications, which in turn are more frequent, 
i.e. patients with a higher comorbidity, additional procedures and more than one 
metastatic site. Patients in HVH may have undergone a more thorough surveillance 
before hospitalization and selection for surgery, especially in a metastatic setting, 
which is more stringent and rigorous[275] . Hospitals with a high number of beds and 
a high volume of surgeons have fewer complications. For sure, post-operative 
complications will occur to a certain extent in every hospital performing surgery, so 
the process of care involved in detection must be addressed. An awareness of early 
signs of complications and to be able to diagnose them is important in this regard. 
Care providers must be able to handle complications in a timely manner to avoid 
serious adverse outcomes. A complex interplay underlies postoperative mortality. 
General requirements such as multidisciplinary teams and 24-hour intensive care 
units are of course important, but it is important not to forget is the establishment of 
adequate counseling and routines at discharge to discover complications that occur 
post–discharge, in order to reassure that patients are re-admitted when needed.  
In this surgical cohort, 29 patients died within 30 days from 2008-2013. Could these 
“29 failure-to-rescue” have been avoided? We are not able to answer this, but the 
causes of deaths reported in our study coincide with results from other studies [212]. 
In our study, five deaths were classified as procedure related, four from intestinal 
injuries and one from hemorrhage. The rest were related to cardiovascular conditions, 
infectious diseases or multi-organ failures, and from the KC itself.  
LVH did PN and MIM to a lesser extent, and additionally had a higher rate of 
conversions from MIM-RN to ORN. Generally speaking, the TDM was higher 
among converted patients, illustrating that more than one procedure adds to the 
complexity. This observation may indicate the need for an adequate yearly surgical 
load is > 20/year to introduce and routinely use advanced techniques, such as, e.g., 
MIM-RN and MIM-PN.  In addition, HVH may practice a higher threshold to operate 
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on patients with a poor performance status, and may be more willing to introduce 
surveillance as an option for comorbid patients. 
5.3.2 Long-term survival 
In Paper II, different tests were performed to help analyze survival for surgically 
treated patients with tumors <7 cm. Kaplan-Meier Plots showed a better OS for 
patients undergoing PN than RN. In a Cox analysis, PN was an independent predictor 
for OS in addition to age, stage and grade. No difference in CSS was found when 
stratified for stage. The five-year RS was higher for PN than RN, though it was not 
significant. These findings support and amplify PN as a contributor to better survival. 
However, Schuch et al. question this in a study in which patients undergoing RN and 
PN were compared with non-cancer controls. RN showed a similar OS as non-cancer 
controls and PN did better, thus suggestive of a selection bias for the latter group. 
Nonetheless, the patients were 10 years older than the average KC patient. They 
propose that the survival advantage of PN is a result of biased observational data. 
More research is needed to solve this ongoing debate on the OS gain. We performed 
competing risk analyses to investigate this more closely, and found a higher 
probability of death after RN from competing risks, but with an early separation of 
the curves. The most important finding is when dividing other causes of death in non-
cancerous and other cancer deaths, the curves starts to diverge at two years, hence 
reflecting similar a competing risk for PN or RN in the beginning, but increasing for 
patients with RN thereafter. This demonstrates that even though unmeasured 
confounders might be present, it looks like a non-cancerous survival effect for PN 
exists, which can be partly due to a better preserved renal function. 
5.3.3 RMB and survival 
Survival was also focused on in Paper I. The causes of death were studied among 
patients who had done RMB or not. Not surprisingly, patients with localized KC who 
underwent RMB had a higher likelihood of dying of causes other than KC. This 
illustrates that a pretreatment evaluation was done, and that only if a biopsy 
uncovered malignity should surgery be rendered as an alternative. RMB is usually 
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performed in patients who are comorbid and presenting an increased risk of intra- and 
postoperative complications, in addition to a limited life expectancy [70]. 
Patients on observation with no active treatment had a higher probability of especially 
dying from other causes, and secondly from KC, than those undergoing active 
treatment (surgery). It is likely to be believes that for patients without active 
treatment, the burden of comorbid diseases prohibited surgery. Surveillance is also 
recommended when the probability of non-RCC deaths overshadow the risk of RCC 
progression [276]. 
To obtain systemic treatment for patients with mRCC, a histopathological verification 
of ccRCC from the primary tumor or metastasis was needed. Patients with a poor 
performance status, and with a severe comorbidity and advanced disease who are not 
candidates for treatment, are not likely candidates for biopsy either [133]. In our 
material, patients without RMB or CN had the poorest outcome regarding survival, 
and performed significantly worse than those who had RMB with no CN. Today, 
RMB is used as an integrated part of an active customized treatment strategy for 
mRCC. New treatments have shown less side-effects, and in the future even more 






6. Strength and Limitations  
6.1 Strengths 
Many studies are based on joint databases, which partly include whole nation data or 
rely on self-reporting by surgeons. To the contrary, the present study is strengthened 
by the fact that CRN has more and independent reporting routines, which enhances 
the completeness of the registry database at CRN, and improves the outcomes of 
studies. Its completeness is close to 100%, and is considered to be reasonably 
accurate and timely [277]. The strength of this study is also that all CRN data was 
manually quality assured from registry sources, including a reevaluation of histology 
reports, staging and biopsy/surgical procedure. Survival data was also regularly 
updated. 
6.2 Limitations 
The CRN does not harbor information about tumor complexity, renal function, 
clinical data on comorbidity , complications and performance status all of which 
would have been valuable and deepened the understanding of the results.  With such 
data available, the question of “failure to rescue” rates could have been better 
addressed in Paper III since the ability to avoid mortality after surgery is associated 
with both complications and comorbidity [275, 278].  
Because hospitals, surgeon experience, practice setting and their annual caseload 
were all anonymous, their influence on selection and the diffusion of treatment could 
not be evaluated. Lack of the latter, as well as data on accompanying diseases and 
history of prior surgery, could be possible confounders. 
Data on hospital stay and surgical conversion were incomplete in 2008-2009; 
therefore, those two years are excluded from any analysis on these years. 
The numbers of deaths in Paper III were low; hence, there is a risk of overfitting in 
the multivariate analysis.  
A major limitation of the study population in Paper I is the lack of data on patients 
with benign renal tumors. Consequently, few conclusions on the pretreatment use of 
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RMBs and final outcome for this relatively large group can be drawn. Lack of 
specific information on how the biopsies were taken, the numbers of cores and of 
earlier non-diagnostic biopsies is missing. Moreover, tumor grading is often not 
registered, so the results should therefore be interpreted accordingly. 
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7. Conclusion  
 For patients with localized KC, the increased use of RMB is partly driven by a 
doubling of RMB among patients for observation. RMB is more frequently 
used in older patients with smaller tumors, with multiple tumors and with a 
second primary malignancy.  
 Fewer patients with advanced KC were treated without a histopathological 
verification at the end of the study period. The majority of biopsies were 
performed in patients who had CN. 
 RMBs in Norway seem to be in line with the indications in current 
international guidelines. 
 For tumors ≤ 7 cm, the study demonstrated an overall increase of 28% in 
surgically treated patients, which was a result of increased PN, as the numbers 
of RN were stable.  
 The use of PN increased significantly for tumors ≤ 4cm, and slightly for 
tumors 4.1-7cm.  Open surgery decreases and MIM increases for both RN and 
PN. The treatment shiftt coincides with new guideline recommendations from 
2010.  
 Patients undergoing PN ≤ 7 cm seem to have an improved OS and RS 
compared to similar RN patients. 
 Among all surgically treated KC patients, TDM after KC surgery was 0.9% 
overall, which is in line with previous reports.  
 For all stages, TDM was higher in older age groups, and significantly lower 
for PN and MIM procedures. 
 Patients treated at LVH have significantly poorer outcome in terms of TDM. 
 The study supports the new hospital –volume regulation from the Norwegian 




8. Future perspectives  
A systematic registration of comorbidity, kidney function, surgery, peri-operative and 
follow-up data is clearly needed in order to surveil the quality of the KC diagnostics, 
treatment and outcome. A dedicated kidney tumor registry modelled on, e.g., the 
National Swedish Kidney Cancer Registry [18] , is warranted.  
We believe that a registry represents a unique opportunity to understand Norwegian 
practice- and referral patterns. It could assist in developing better regional- and 
national treatment algorithms, thereby assuring a suitable catchment area for the 
different treatment options. Patients should be offered uniform treatment, irrespective 
of their region of residence.  
 
The future will probably bring a more active attitude to active surveillance. It could 
be that renal mass biopsy should be mandatory for all in order to avoid unnecessary 
surgery and morbidity. In many other malignancies, the cancer diagnosis is verified 
before surgery, and this is likely what lies ahead for both KC and RCC as well. 
The multidisciplinary approach to metastatic RCC challenges the partnership between 
surgeons and oncologists more than before. Patients deserve the best sequencing of 
different systemic treatments and surgery, and dedicated urologists and oncologists 















2009 TNM staging classification of renal cell carcinoma 
 
T-primary tumor 
TX  Primary tumor cannot be assessed 
T0  No evidence of primary tumor 
T1  Tumor  ≤ 7 cm in greatest dimension, limited to the kidney 
 T1a Tumor  ≤ 4 cm in greatest dimension  
 T1b Tumor > 4cm but  ≤ 7 cm in greatest dimension 
T2  Tumor > 7 cm in greatest dimension, limited to the kidney 
 T2a Tumor > 7 cm but  ≤ 10 cm 
 T2b Tumor > 10 cm, limited to the kidney 
T3  Tumor extends into major veins or perinephric tissue but not into the ipsilateral 
adrenal gland or beyond Gerota`s fascia 
 T3a Tumors  grossly extends into renal vein, segmental muscle containing branches or 
invades perirenal and/or  renal sinus fat(peripelvic), but not beyond Gerota`s fascia 
 T3b Tumor grossly extends into the vena cava(VC) below the diaphragm 
 T3 c Tumor extends into vena cava above the diaphragm or invades the wall of  VC 
T4  Tumor invades beyond Gerota`s fascia (including contiguous extension into the 
ipsilateral gland) 
N-Regional Lymph nodes 
NX  Regional LNs cannot be assessed 
N0  No regional LN metastasis 
N1  Metastasis in a single regional lymph node 
N2  Metastasis in more than one regional lymph node 
Distant metastasis 
MX  Metastasis cannot be assessed 
M0  No distant metastasis 
M1  Distant metastasis 
TNM stage grouping 
Stage I T1 N0 M0 
Stage II T2 N0  M0 
Stage III T3 N0 M0 
 T1,T2,T3 N1 M0 
Stage IV T4 Any N M0 
 Any T N2 M0 
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Background: Guidelines on surgical treatment for kidney cancer (KC) have changed
over the last 10 yr. We present population-based data for patients with KC tumors 7 cm
from 2008 to 2013 to investigate whether surgical practice in Norway has changed
according to guidelines.
Objective: To assess the predictors of treatment and survival after KC surgery.
Design, setting, and participants: We identified all surgically treated KC patients with
tumors 7 cm without metastasis diagnosed during 2008–2013 (2420 patients) from
the Cancer Registry of Norway.
Outcome measurements and statistical analysis: Relationships with outcomes were
analyzed using joinpoint regression, multivariate logistic regression, Kaplan-Meier
survival estimates, Cox regression, relative survival (RS), and competing-risk analyses.
Results and limitations: The mean follow-up was 5.2 yr. There was a 28% increase in
the number of patients undergoing surgical treatment over the study period. Joinpoint
regression revealed a significant annual increase in partial nephrectomy (PN) and a small
reduction in radical nephrectomy (RN). PN increased from 43% to 66% for tumors 4 cm
and from 10% to 18% for tumors of 4.1–7 cm. Minimally invasive (MI) RN increased from
53% to 72% and MI PN from 25% to 64%, of which 55% of procedures were performed with
robotic assistance in 2013. The geographical distribution of treatment approaches
differed significantly. Both PN and MI approaches were more frequent in high-volume
hospitals. Cox regression analysis revealed that PN, age, and Fuhrman grade and stage
were independent predictors of survival. There were no significant differences in cancer-
specific survival (p = 0.8). The 5-yr RS for T1a disease was higher after PN than after RN.
Conclusions: The rate of PN for tumors 7 cm increased in the 6-yr study period. MI
approaches increased for both RN and PN. This treatment shift coincides with the new
guideline recommendations in 2010. The possible better survival for patients undergoing
PN compared to RN indicates the importance of following evidence-based guidelines.
Patient summary: The use of partial nephrectomy and minimally invasive surgery for
kidney cancer tumors increased in Norway from 2008 to 2013 according to population-
based data, coinciding with guideline changes. The study illustrate that adherence to
guidelines may improve patient outcomes.
© 2018 Published by Elsevier B.V. on behalf of European Association of Urology.
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1. Introduction
In Norway, the incidence of kidney cancer (KC) increased by
52% over the course of one decade (2007–2016) [1], with
similar observations in Europe and worldwide [2]. Surgical
treatment is still the mainstay of intervention for localized
KC. Partial nephrectomy (PN) has oncological outcomes
similar to radical nephrectomy (RN) for tumors 7 cm
[3]. Furthermore, several retrospective studies have sug-
gested that PN patients may achieve better overall survival
(OS) [4–7], most likely attributed to lower impairment of
renal function. However, recent publications have chal-
lenged this possible OS gain for PN over RN, claiming that it
is caused by selection bias [8]. Since the early 1990s, the
“pure” laparoscopic and later the robot-assisted laparo-
scopic approach to kidney surgery evolved to complement
the RN and PN open approaches. It has been shown that
minimally invasive methods (MIMs) have equivalent
oncological outcomes to open surgery [9] and add benefits
such as less surgical trauma, lower morbidity, and shorter
hospital stays [10].
From 2006, the European Association of Urology (EAU)
guidelines recommended PN as the standard of care for
tumors 4 cm and as an option in experienced centers for
selected patients with tumors of 4.1–7 cm [11]. In 2010, the
EAU recommendation changed significantly, as PN then
became the standard of care for all tumors 7 cm.
Moreover, a laparoscopic approach was recommended for
RN if PN was not indicated [12].
On this basis, we aimed to establish updated population-
based Norwegian data on KC surgery for tumors 7 cm.
Furthermore, we evaluated adherence to changing guidelines
and the implementation of MIMs and PN. Finally, predictors
for treatment and survival after surgery were assessed.
2. Patients and methods
2.1. Data source, data extraction, exclusions, and quality
assurance
Data sets for all 4465 kidney cancer patients in Norway (ICD-10 code
C64) diagnosed during the 6-yr period from 2008 to 2013 were extracted
from the Cancer Registry of Norway (CRN) database. Information on
reporting and the CRN is provided in the Supplementary material. The
data sets consist of demographic, tumor-related, treatment-related, and
follow-up (FU)-related variables. Information on kidney function,
comorbidity, and complication rates was not available. Data quality
assurance and removal of erroneously registered patients (n = 16) was
performed at the CRN, and has been previously described [13]. Thereafter,
data sets for 4449 patients were transferred to an anonymous database
for subsequent analyses. Of these, 2420 patients aged >18 yr with N0M0
KC 7 cm and surgically treated with PN or RN remained within the data
set. Figure 1 shows details for the inclusion and exclusion of patients. In
accordance with national regulations, the study did not require informed
consent from the patients when performed at the CRN.
2.2. Definitions used for analyses
Patients were classified as N0M0 if they had no nodal or distant
metastasis at the time of surgery or within 4 mo thereafter. Details on
staging and follow-up are described in the Supplementary material. For
tumor staging, the 2009 version of the TNM classification was used
[14]. Tumor size was based on the histology report, whereas survival and
FU were estimated from data received from the Norwegian Cause of
Death Registry dated December 31, 2016. Open operations were
classified as those that started as open or were converted from a MIM
approach to open surgery. Procedures classified as RN started as RNs or
were PNs converted to RN during surgery. MIMs included pure
laparoscopy, hand-assisted laparoscopy, and robot-assisted laparoscopy.
Norway is subdivided into 19 counties and the health care system is
organized in four regional health authorities (HAs): the Northern (NHA),
Central (CHA), Western (WHA), and South-Eastern (SHA) HAs. Hospitals
performing KC surgery were divided into two groups on the basis of
national volume recommendations according to their mean annual
surgical volume: low-volume hospitals (LVH) performed <20 KC
operations/yr, while high-volume hospitals (HVH) performed 20 KC
operations/yr [13,15]. Hospitals performing fewer than four KC surgeries
during the study were excluded.
2.3. Statistical analysis
Standard descriptive statistics were used, with results presented as the
mean  standard error of the mean (SEM). The median and interquartile
range (IQR) were used for descriptions of variation within groups. We
used t tests and x2 tests for comparisons of continuous and categorical
variables, respectively.
Multiple logistic regression models were established without any
preselection of the variables. Survival estimates, OS and cancer-specific
survival (CSS) were calculated using the Kaplan-Meier method. Relative
survival (RS) was calculated using the Pohar-Perme method [16]. Cox
regression was performed to identify predictors of OS, with the hazard
ratio (HR) and 95% confidence interval (CI) reported. Conditional
probability estimates for death were calculated for different groups
with competing risks. Joinpoint regression analysis was carried out using
Joinpoint Regression v.4.5.0.1 (https://surveillance.cancer.gov/joinpoint)
[17]. Statistical significance was set at p < 0.05. Calculations were




The mean observation time from surgery to death or last FU
was 5.2 yr (median 5.0, range 3.8–6.6). Patients undergoing
RN were older (64.8 vs 61.2 yr; p < 0.001) and had larger
tumors (4.3  0.04 vs 2.7  0.04 cm; p < 0.001) than those
undergoing PN.
The male/female ratio was 1.9:1. There was no difference
between the RN and PN groups for gender (p = 0.23) or
tumor size (p = 0.1). Table 1 lists patient, tumor (including
stage, grade, and histopathological subtypes), and treat-
ment characteristics for the whole cohort.
3.2. Treatment status and changes
3.2.1. Nationwide
There was a 28% overall increase in surgical treatment of
patients with a KC tumor 7 cm. The number of patients
who underwent RN yearly was stable, while the number of
patients undergoing PN doubled from 2008 to 2013
(Supplementary Table 1). Joinpoint regression analysis
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revealed an increase in the use of PN and a decrease in the
use of RN (Fig. 2). Throughout the study period, 58% of
tumors 4 cm were treated with PN and a significant
increase was observed from 2008 to 2013 (43% vs 66%). For
tumors of 4.1–7 cm, only 14% were treated with PN, but with
an increase from 10% in 2008 to 18% in 2013. The
distribution of treatments and time trends are illustrated
in Figure 3 and Supplementary Figure 1. In the RN group,
Fig. 1 – Flowchart for data extraction from the main database of the Cancer Registry of Norway according to the inclusion and exclusion criteria.
MIM = minimally invasive method.
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MIM use increased from 52% in 2008 to 72% in 2013. Figure 3
demonstrates the shift in 2010 towards more MIMs. For PN,
MIM use increased from 25% to 64% during the study period,
and 55% of PNs in 2013 were performed with robotic
assistance (vs 7% in 2008). The major shift in the use of PN
occurred from 2010 onwards, including a gradual increase
in MIM. In 2013, the use of robot-assisted laparoscopic PN
(RALPN) surpassed pure laparoscopic PN (Supplementary
Table 1). The use of MIM-PN and open partial nephrectomy
(OPN) was similar between the age groups (<65 vs 65 yr);
by contrast, MIM-RN was used significantly more often than
open radical nephrectomy (ORN) for patients <65 yr (70% vs
60%; p = 0.004).
3.2.2. Regional and county trends
The geographic distribution of PN versus RN and open versus
MIMs differed significantly between the regions, as illustrated
in Supplementary Figure 2 (p < 0.001). RN was used more
frequently for patients within the SHA (62%) and NHA (63%)
compared to the CHA (55%) and WHA (45%). The most
frequent procedure was laparoscopic RN (LRN) in the SHA and
OPN in the WHA. In each region, PN increased significantly
from the first to the second half of the study period, but
differences persisted (p < 0.03). The distribution of treatment
types by HA and year is shown in Supplementary
Figure 2. Patients living in the 19 counties experienced
divergent treatment strategies, although with a trend towards
an increase in PN use for all counties, as shown in Figure 4.
3.2.3. Hospital trends
The tumor size distribution did not differ between HVHs
and LVHs, although HVHs used PN for KC surgery more often
than LVHs (44% vs 33%; p < 0.001). This was particularly
evident for tumors 4 cm (p < 0.001) but was less
pronounced for tumors of 4.1–7 cm (p = 0.295). PN use
increased from the first to the second period at both HVHs
(from 36% to 51%) and LVHs (from 24% to 38%), despite no
change in tumor size.
3.3. Predictors of treatment
To identify predictors of PN, several factors were entered
into a multivariate logistic regression model (Table 2).
Younger age, smaller tumor size, HVH, second half of the
study period, and WHA and CHA remained independent
predictors. Furthermore, the independent predictors of
undergoing MIM surgery were female gender, HVH, second
half of the study period, and SHA.
Table 1 – Characteristics of patients with a kidney cancer tumor 7 cm (N0M0) surgically treated during 2008–2013
Overall RN PN p value
Patients, n (%) 2420 (100) 1406 (58.1) 1014 (41.9)
Age (yr) <0.001 a
Mean  SEM 63.3  0.2 64.8  0.3 61.2  0.4
Median (range) 65 (18–92) 66 (18–92) 63 (18–89)
Gender, n (%) 0.2 b
Female 845 (35) 505 (36) 340 (34)
Male 1575 (65) 901 (64) 674 (66)
Side, n (%) 0.03 b
Right 1225 (51) 706 523
Left 1178 (49) 697 482
Bilateral 10 (0) 5 5
Not specified 7 (0) 2 5
Tumor size (cm)
Mean  SEM (median) 3.6  0.03 (3.5) 4.3  0.04 (4.4) 2.65  0.04 (2.5) <0.001 a
4 cm (n = 1553) 2.6  0.02 (2.5) 3.0  0.03 (2.2) 2.3  0.03 (3.0) <0.001 a
>4 to 7 cm (n = 867) 5.5  0.03 (5.3) 5.6  0.03 (5.5) 5.0  0.07 (5.0) <0.001a
Subtype, n (%) <0.001 b
Clear cell 1701 (70) 1028 (73) 673 (66)
Papillary 407 (17) 197 (14) 210 (21)
Chromophobe 149 (6) 85 (6) 64 (6)
Multicystic clear cell 76 (3) 35 (2) 41 (4)
Other kidney cancers 87 (4) 61 (4) 26 (3)
Fuhrman grade, n (%) <0.001b
1 269 (11) 124 (9) 145 (14)
2 1314 (54) 742 (53) 572 (56)
3 544 (23) 366 (26) 178 (18)
4 61 (2) 50 (3) 11 (1)
Not specified 232 (10) 124 (9) 108 (11)
T stage, n (%) <0.001 b
pT1a 1497 (62) 614 (44) 883 (87)
pT1b 716 (30) 604 (43) 112 (11)
pT3a 193 (8) 174 (12) 19 (2)
pT3b 9 (0) 9 (1) 0 (0)
pT4 5 (0) 5 (0) 0 (0)
RN = radical nephrectomy; PN = partial nephrectomy; SEM = standard error of the mean.
a According to a t test between the RN and PN groups.
b Exact 2 test for comparison between the RN and PN groups.
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3.4. Survival analyses
Kaplan-Meier plots showed an OS benefit for patients
undergoing PN compared to RN (Supplementary Figs. 3 and
4). On Cox regression analysis, PN was an independent
predictor of OS, as were age, Fuhrman grade, and T stage
(Supplementary Table 2). There was no difference in CSS
between PN and RN when stratified for stage (p = 0.8).
Although the difference is not significant, the 5-yr RS was
higher for the PN group (98.1, 95% CI 94.0–99.4) than for the
RN group (92.8, 95% CI 88.1–95.7). For T1b tumors the 5-yr
RS was 98.8 (95% CI 16.3–100.0) after PN and 90.0 (95% CI
85.1–93.3) after RN. Competing-risks analysis (Fig. 5A)
revealed a higher probability of death from competing risks
in the RN group, with early separation of the curves for RN
and PN. However, after splitting other-cause deaths into
other cancers and noncancerous conditions (Fig. 5B), PN and
RN patients had a similar probability of death from a
Fig. 2 – Temporal trends in the use of (A) partial nephrectomy and (B) radical nephrectomy for 2420 patients. Data points show the annual frequencies
and the trend line demonstrates the joinpoint regression results. The annual percentage change (APC) was significantly different from zero at
a = 0.05 for partial nephrectomy, indicating a significant increase in this procedure. The small decrease in radical nephrectomy was not statistically
significant.
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noncancerous condition the first 2 yr before the curves
separate, and the competing risks increase for RN patients.
Figure 5C shows similar separation of the curves comparing
death from all cancers to death for noncancerous condi-
tions.
4. Discussion
The present study clearly demonstrates that the field of KC
surgical care and management is rapidly changing. Over the
past 20 yr the toolbox for personalized surgical treatment of
Fig. 3 – Comparison of treatments in terms of percentage of procedures per year. (A) All approaches investigated. (B) Open radical nephrectomy
(ORN) versus minimally invasive radical nephrectomy (MIM-RN). (C) Open partial nephrectomy (OPN) versus minimally invasive partial nephrectomy
(MIM-PN).
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Fig. 4 – Distribution and changes in treatment in the 19 counties in Norway in the first half (2008–2010) and second half (2011–2013) of the study
period. PN during (A) 2008–2010 and (B) 2011–2013. (C) PN for tumors 4 cm during (C) 2008–2010 and (D) 2011–2013. MIM-RN for tumors of 4.1–7 cm
during (E) 2008–2010 and (F) 2011–2013. MIM includes pure laparoscopic, hand-assisted, and robot-assisted laparascopic methods. Overall, the
variation in PN among counties ranged from 26% to 59%. The variation in PN rate ranged from 36% to 77% for tumors 4 cm and from 2% to 28% for
tumors of 4.1–7 cm (data not shown). Counties with a PN rate of <25% PN in 2008 doubled the PN rate in 2013, whereas counties with a PN rate of 25–
40% in 2008 increased this to approximately 60% in 2013. Four of the 19 counties generally used PN more often than RN during the study period. From
the first to the second half of the study, the use of MIM-RN for tumors of 4.1–7 cm became more widespread. PN = partial nephrectomy; MIM-
RN = minimally invasive radical nephrectomy.
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renal tumors has expanded. In the past, most urology
surgeons had one standard open surgical procedure for all,
but today urologists face multiple choices regarding both
the surgical approach (standard, single site, hand-assisted,
or robot-assisted laparoscopy) and tumor removal (RN vs
PN). Moreover, ablative treatments and surveillance could
be appropriate alternatives. In this changing landscape,
evidence-based guidelines are important contributors in
helping to choose the best treatment for individual KC
patients. One of the important changes demonstrated in
this study is the marked increase in PN following the major
change in the EAU recommendation for PN in 2010. The
overall use of PN in Norway increased from 31% to 49%
between 2008 and 2013. The implementation was greatest
for tumors 4 cm (66% in 2013), but was also substantial for
tumors of 4.1–7 cm (18% in 2013). This is in line with current
evidence-based knowledge on the surgical treatment of
localized KC tumors of 7 cm, which advocates PN rather
than RN whenever feasible [12]. The current data show that
use of PN in Norway is comparable to recent Dutch and
Swedish population-based data. In the Dutch study, the use
of PN was 62% for T1a and 30% for T1b tumors in 2014, while
in the Swedish study it was 53% for T1a and 9% T1b tumors
in 2011 [18,19]. Similar data are also available from the USA
[20,21].
Similar to the more widespread adoption of PN, MIM use
has also increased. This trend is evident for both MIM-RN
and MIM-PN. MIM is popular among patients because of
lower perioperative morbidity and better cosmetic results
[22]. In studies on quality of life after KC surgery,
laparoscopic procedures performed better than open
surgery [23]. Pure laparoscopic PN is a more challenging
procedure than LRN. It requires considerable surgical
expertise, which may have limited its implementation.
The learning curve for RALPN seems shorter than for pure
laparascopic PN [24], and RALPN is also favorable in terms of
complications, conversions, and ischemia time [25]. Costs
for the purchase and maintenance of the robotic platform
are considerable, and therefore acquisition is not warranted
in every hospital [26,27]. However, when RALPN is available,
it increases the adoption of PN [27,28].
The data from the first half of the present study reflect the
EAU recommendation of PN as an established treatment, and
national guidelines calling for all tumors 4 cm to be
evaluated for PN before treatment [11,29]. These guidelines
offer great latitude for individual surgeons to decide on
Table 2 – Multiple logistic regression analyses to predict PN and MIM in surgically treated kidney cancer patients
Variable PN vs RN (n = 2420) MIM vs open (n = 2396)
OR (95% CI) p value OR (95% CI) p value
Age (continuous in years) 0.97 (0.96–0.98) <0.001 0.99 (0.99–1.00) 0.6
Gender (male vs female) 1.20 (0.97–1.39) 0.20 0.81 (0.67–0.98) 0.03
Tumor size (continuous in cm) 0.42 (0.39–0.45) <0.001 1.02 (0.96–1.07) 0.6
Year of diagnosis <0.001 <0.001
2008–2010 1.00 (reference) 1.00 (reference)
2011–2013 2.17 (1.73–2.58) <0.001 1.93 (1.61–2.31) <0.001
Hospital volume <0.001 <0.001
<20 procedures per year 1.00 (reference) 1.00 (reference)
20 procedures per year 1.87 (1.45–2.46) <0.001 2.2 (1.78–2.88) <0.001
Regional Health Authority <0.001 <0.001
South-Eastern 1.00 (reference) 1.00 (reference)
Western 3.0 (2.26–3.89) <0.001 0.20 (0.16–0.25) <0.001
Central 2.1 (1.55–2.75) <0.001 0.44 (0.34–0.56) <0.001
Northern 1.2 (0.84–1.73) 0.3 0.13 (0.09–0.18) <0.001
PN = partial nephrectomy; RN = radical nephrectomy; MIM = minimally invasive method; OR = odds ratio; CI = confidence interval.
Fig. 5 – Competing-risks analysis for partial nephrectomy (PN) and radical nephrectomy (RN). Probability of death (A) from kidney cancer versus death
from all other causes; (B) from kidney cancer versus other cancers and noncancerous conditions; and (C) from all cancers (including kidney cancers)
versus noncancerous conditions.
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treatment according to their own preferences. The important
change in the 2010 edition of the EAU guidelines was the
recommendation of PN “whenever possible” and of whether
or not to perform LRN on T1 tumors suitable for PN [12]. This
recommendation probably made the decision to continue
performing open RN for all tumors more difficult for LVHs.
The present study demonstrates that regional discrepancies
were less pronounced in 2013 than earlier, and that the
regional treatment patterns seem to have equalized. More
imperative recommendations might have been a key to this
change. It has been demonstrated that surgeons interpret
terms such as “if technically feasible” differently. In a survey
among American urologists, the willingness to offer PN
depended on the surgeon’s preferences, skill, experience,
practice setting, renal tumor caseload, and percentage PN,
rather than just on tumor size and complexity [30]. In a
Canadian study, high-volume surgeons predicted MIM and
academic status predicted PN [31]. Our study lacks data at
the surgeon level, but obviously more imperative guidelines
force changes in management. This could occur with uptake
of new methods or referral to larger centers. The hospital
volume effect has been discussed in several publications, and
influences the type of surgery, perioperative complications,
morbidity, and mortality [19,30–32]. In our study, we also
found that HVHs were independent predictors of PN. Overall,
the present study indicates that the Norwegian urology
community seems to have adapted relatively quickly to
changing guidelines.
In line with other authors [7,19], we found that
Norwegian patients treated with PN experienced better
OS and RS and that PN independently predicted OS.
Earlier publications have partly related this to better
preserved renal function, as chronic renal insufficiency
represents a dose-dependent risk factor for cardiovascular
diseases and events, risk of hospitalization, and mortality
from any cause [4]. However, a meta-analysis by Wang et al
[33] did not indicate that PN reduced the rate of
cardiovascular events.
Newer findings indicate that only selected groups of
patients presenting with preoperative chronic kidney
disease (CKD) or concomitant comorbidity benefit from
PN [34,35] and that worsening of already existing CKD is
faster and more pronounced after RN than after PN, possibly
leading to more subsequent deaths among RN patients. The
additional contribution of medically induced CKD to
outcome when compared to surgically induced CKD is also
important [36].
There is an ongoing debate on whether the OS gain after
PN is caused by selection bias [37]. Even though our study is
population-based, selection bias and unmeasured confoun-
ders might be present, and should be kept in mind when
considering the degree of survival benefit for PN, as
discussed by others [8,37]. However, our competing-risks
analysis demonstrates that it takes approximately 2 yr
before the noncancer mortality rates for PN and RN separate,
indicating a lesser degree of selection bias in this group of
patients. On the basis of our data, we cannot rule out that the
less steep noncancer mortality rate is partly due to improved
renal function, but further research is warranted.
The present study is not without limitations. The CRN
register data do not include information about tumor
localization and complexity, renal function, or clinical data
such as Charlson comorbidity scores and postoperative
complications. Since hospitals were anonymous, as was
surgeon experience, practice setting, and annual caseload,
their influence on selection and diffusion of treatment could
not be evaluated.
5. Conclusions
In Norway, the rate of PN for KC tumors 7 cm increased
over the study period. For both RN and PN, the rates of open
surgery decreased while the rate of MIM approaches
increased. The rise in PN observed coincides with the
new guidelines recommendations in 2010.
In general, KC treatment practice in Norway is compara-
ble to that in other countries, but with divergent regional
practice patterns. Patients undergoing PN for KC tumors
7 cm may have better OS and RS compared to similar RN
patients, which supports the importance of following
evidence-based guidelines.
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Part 1- Data Source 
 
As described in earlier publications
1
 , Norwegian clinicians and pathologists (since 
1953) have been requested by law to report all new cases of cancer to the population-
based Cancer Registry of Norway (CRN). Data for all clinical or pathological cancer 
and operation codes used for all types of patient/doctor contacts are transferred to the 
CRN from the national public health-care data systems, and checked against clinical and 
pathological report forms. In case of missing report forms, reminders are sent to the 
various departments. The CRN is connected to the Norwegian Population Registry. The 
registry database contains information on >1,770,000 cancer cases (2016), and has a 
completeness of close to 100%
2
 . Inclusion in the registry is mandatory.  
 
Part 2 - Staging and Follow-up 
This study is based on a national database and does not include data on preoperative evaluation and 
post-operative follow-up in detail. However, in 2007new national guidelines for RCC were 
introduced
3
  and preoperative M-staging with CT of the chest and abdomen were recommended. 
These guidelines have been implemented nationally. A Nordic survey from 2015(including 93% of 
Norwegian KC treating hospitals) was published in 2017
4
 , and demonstrated that chest CT was 
used in > 90% of cases ≤4 cm. Furthermore, as described in a study from our hospital
5
 and 
published in 2015, the overall use of preoperative chest CT was 94.6% during the years 2007-2013. 
As Norway is a relatively homogenous society, it is reasonable to assume that most patients have 
been staged for distant metastasis according to generally accepted rules.  
N-staging is based on what is reported on histopathology reports and as a result of preoperative 
imaging.  
When it comes to follow-up (FU), details for each hospital are not collected in the registry. The 
Norwegian standard of FU has been FU visits every six months for 5-years with at least chest X-
ray for low-risk RCC and CT-scans for the higher risk groups. In 2007 our department launched a 
risk stratified FU-program that has been widely accepted and used in Norway. The program and 
results has been published in 2016
6
. In our opinion, there is no reason to believe that FU in Norway 
has been of a lesser quality than recommended in international guidelines during the study period. 
However, as data for FU is not included in the national database, we have not looked disease 
free/metastasis free survival. We have focused on cancer specific and overall survival, as these data 
are collected from national death certificates. 
Patients were described as N0 M0 if they had no nodal metastasis or distant metastasis at the time 




Part 3 - Thermal ablation and active surveillance 
The scope of the present study was surgical treatment of KC, and therefore patients treated 
with thermal ablation (TA) and active surveillance (AS) was not included.  In Norway 
utilization of TA has been limited. Only seven patients with kidney cancer ≤ 7cm N0M0 
were treated with TA during the study period (2008 – 2013) (figure 1). Regarding AS, our 
data on this is unfortunately not complete. However, we know that approximately 5-6 % of 
patients diagnosed with localized KC in Norway did not undergo any kind of active 





Part 4 - Acquisition and availability of the robotic platform in Norway 
Today 15 robotic systems are distributed in Norway. Norwegian Urologic surgeons started 
with prostatectomies and secondly partial nephrectomies.  
The first robotic system was installed in the South Eastern Regional Health Authority in 
2004, the second and the third in 2007, the fourth in 2012, the fifth in 2015, the sixth in 
2016, the seventh  in 2017 and the latest bought by a private  health care  company this 
year. The first robotic kidney surgery was done in 2006, but as illustrated in supplementary 
table 2, few such surgeries were performed the first years. 
In the Western Regional Health Authority the two first robotic platforms were achieved in 
2009, and the first robotic kidney surgery was done autumn 2010.  
The Central Regional Health Authority acquired their first robotic system in 2010, and 
started also with kidney surgery late the same year (they achieved their second robot in 
2012). 
In the Northern Regional Health Authority one robotic system was installed in 2012 and 











Supplementary figure 1 - Trends in treatment 2008–2013 illustrated in bar diagrams 
A: Distribution of Radical Nephrectomy (RN) and Partial Nephrectomy (PN) in 
numbers/year. B: Distribution of RN and PN for tumors ≤4cm and 4.1 ≤ 7cm in 
numbers/year. C: Distribution of Open Radical Nephrectomy (ORN), Minimal Invasive 
Radical Nephrectomy (MIM-RN), Open Partial Nephrectomy (OPN) and Minimal Invasive 
Partial Nephrectomy (MIM-PN) in numbers/year. Minimal Invasive includes both the pure 
laparoscopic, hand-assisted and robot-assisted method. 
 
Supplementary figure 2 - Distribution of treatment in the four Regional Health Authorities.  
Open Radical Nephrectomy (ORN), Minimal Invasive Radical Nephrectomy (MIM-RN), 
Open Partial Nephrectomy (OPN) and Minimal Invasive Partial Nephrectomy (MIM-PN). 
Minimal Invasive includes both pure laparoscopic, hand-assisted and robot-assisted method. 
 
Supplementary figure 3 - Kaplan-Meier plot demonstrating survival probability for Partial 
Nephrectomy (PN) and Radical Nephrectomy (RN):  
Solid line (blue) – PN (1011 patients at risk initially, 71 still at risk after 8 years) 
Dotted line (orange) – RN (1401 patients at risk initially, 152 still at risk after 8 years) 
 
Supplementary figure 4 - Kaplan-Meier plot demonstrating the survival probability for 
Partial Nephrectomy (PN) and Radical Nephrectomy (RN) stratified for stages T1a, T1b and 
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Supplementary table 1: Distribution of surgical treatment for kidney cancers ≤ 7 cm 2008-2013  
* Laparoscopic, not robotic, ** Not specified, numbers – numbers of patients 
 Total Radical  Nephrectomy (RN) Partial Nephrectomy (PN) 
            
           
Year  RN Open Lap* Robotic Nos** PN Open Lap* Robotic Nos** 
            
2008 349 241 108 126 0 7 108 75 20 7 6 
2009 345 237 108 124 0 5 108 67 26 12 3 
2010 384 238 91 147 0 0 146 75 51 20 0 
2011 455 235 75 148 11 1 220 124 55 40 1 
2012 441 226 54 155  16 1 215 88 71 55 1 
2013 446 229 63 145 21 0 217 76 63 76 2 
            
Total 2420 1406 499 845 48 14 1014 505 286 210 13 
 
Suppl. table 2: Time dependent Cox-regression analysis (n=2186)  



























RN - Radical nephrectomy, PN - partial nephrectomy, cont. – continuous, 
m – Male, f – Female, HR - Hazard ratio, CI - Confidence Interval, 











  Overall survival 
Variables  HR 95% CI p-value 
     
Surgery (RN vs PN)  1.4 (1.09 - 1.80) 0.008 
     
Age (cont. in years)  1.1 (1.05 - 1.07) <0.001 
     
Gender (m vs. f)  1.4 (1.14 - 1.74) 0.002 
     
Histopathology     
 Fuhrman 1  1.0 ref  
 Fuhrman 2  1.5 (1.02 - 2.29) 0.038 
 Fuhrman 3  1.7 (1.14 - 2.67) 0.010 
 Fuhrman 4  3.4 (1.96 - 5.95) <0.001 
      
pT-Stage      
 T1a  1.0 ref  
 T1b  1.1 (0.90 - 1.44) 0.266 
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Background: To improve cancer care in Norway, the government introduced surgical
volume requirements for hospitals in 2015. To treat kidney cancer (KC) in Norway, the
lower limit is 20 surgical procedures per year.
Objectives: To compare the impact of hospital volume on outcome with regard to 30-d
mortality (TDM) following KC surgery.
Design, setting, and participants: We identified all KC patients from the Cancer Registry
of Norway diagnosed during 2008–2013 whose surgical treatment involved partial or
radical nephrectomy. Hospitals were divided into three volume groups: low (LVH),
intermediate (IVH), and high (HVH) volume.
Outcome measurements and statistical analysis: Relationships with outcome were
analysed using multivariate logistic regression.
Results and limitations: In total, 3273 patients were identified. The TDM rate was 0.89%
overall, 0.73% for localised KC, and 2.6% for metastatic KC. The mean (median, inter-
quartile range) numbers of procedures for LVH, IVH andHVHwere 5.2 /yr (3, 1.3–8.7), 27
/yr (26, 23–30) and 53 /yr (53, 48–58), with TDM rates of 2.2%, 0.83%, and 0.39%,
respectively (p = 0.001). In a multivariate logistic regression model, tumour stage, age,
and hospital volume remained independent TDMpredictors. The odds ratio for TDMwas
4.98 (confidence interval 1.72–14.4) for LVH compared to HVH (p = 0.003). Study
limitations include a lack of data for surgical complications and other possible con-
founders.
Conclusions: TDM is associatedwith age, stage, and hospital volume. The study supports
the new regulation for hospital volume introduced in Norway.
Patient summary: The risk of dying within 30 d following kidney cancer surgery is low.
Advanced disease and older age are risk factors for higher mortality. In this study, we
also showed thatmore patients die within 30 d in hospitals performing fewer operations
per year than in hospitals performing many operations.
# 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.
* Corresponding author. Department of Urology, Haukeland University Hospital, P.O. Box 1400,
Bergen N-5021, Norway. Tel. +47 55 972902; Fax: +47 55 972050.
E-mail address: christian.beisland@helse-bergen.no (C. Beisland).
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1. Introduction
Surgical treatment is still the mainstay of treatment for
kidney cancer (KC). Therefore, perioperative mortality is an
important quality indicator for patient outcomes [1]. In the
literature, contemporary perioperativemortality (both 30-d
mortality [TDM] and in-hospital mortality [IHM]) is
reported as 0.5–1.5% for localised KC and 2–4% for
metastatic (M+) KC [2–7]. For several surgical treatments
for other malignancies and for benign conditions, hospital
volume is an important factor that significantly affects
outcomes [8–10]. However, studies evaluating the impact of
hospital volume on outcomes for KC surgery are sparse.
Furthermore, there is no generally accepted definition of a
low- or high-volume hospital.
Acknowledging that surgical volume is most likely
associated with improved patient outcomes, the Norwegian
health authorities introduced requirements in 2015 for
hospitals that should continue to perform cancer surgery
[11]. In addition to general requirements for hospitals to
havemultidisciplinary teams, 24-h intensive care units, and
documented adherence to guidelines, specific volume
demands for hospitals and surgeons were established. For
KC, hospitals must perform at least 20 surgical procedures
per year to remain operative.
Against the background of these new hospital volume
requirements, we investigated the relationship between
hospital volume and TDM in a national population-based
setting. We used other well-recognised (age, stage) [3,12]
and potential (surgical procedure, gender) [6,12] prognostic
factors as covariates in the study. The study aim was to
establish updated Norwegian population-based TDM rates
for KC surgery.
2. Patients and methods
2.1. Data source
Since 1953, Norwegian clinicians and pathologists have been required by
law to report all new cases of cancer to the population-based Cancer
Registry of Norway (CRN). Data for all clinical and pathologic cancers and
operation codes used for all types of patient-doctor contact are
transferred to the CRN from the national data systems for public health
care, and checked against clinical and pathologic report forms. In the
case of missing report forms, reminders are sent to the various
departments. The CRN is further connected to the Norwegian Population
Registry. The registry database contains information on >1 700 000
cancer cases up to 2015, and has completeness of close to 100%
[13]. Inclusion in the CRN is mandatory. Thus, in accordance with
national regulations, our study did not require informed consent from
patients for data extraction from the CRN. The registry does not include
data for benign kidney tumours.
2.2. Data extraction, exclusions, and quality assurance
Using the CRN, data sets for all 4465 KC patients (ICD-10 code C64)
diagnosed during the 6-yr period from 2008 to 2013were extracted from
the primary database. The data sets consist of demographic, tumour-
related, treatment-related, and follow-up variables. A subset of data
(80%) for hospital stay and surgical conversions was available and
consisted of all patients for 2010–2013, but data were missing in part for
the two first study years.
All CRN data used in the study were manually quality assured from
the registry sources by one author (K.M.H.), including re-evaluation of all
histopathology reports. During this process, 16 patients (0.36%) were
excluded because of a diagnosis other than renal cell carcinoma (RCC).
Then data sets for 4449 patients were transferred to an anonymous
database for subsequent analyses. Of these, 3313 patients aged 18 yr
and treated with partial (PN) or radical nephrectomy (RN) remained
within the data set.
We excluded patients treated at hospitals performing fewer than four
procedures in 6 yr (average of 0.5 /yr) on the assumption that these
hospitals do not treat KC on a regular basis. In this step, 40 patients were
excluded. Hence, the final study population consisted of 3273 patients.
Figure 1 shows the details for inclusion and exclusion of patients.
2.3. Definitions used for analyses
Localised KC was defined as disease without distant metastases (M0) at
diagnosis or within 4 mo thereafter [14]. Metastatic KC was defined as
M+ disease. For tumour staging, the 2009 version of the TNM
classification was used.
TDM was defined as death from any cause within 30 d following
surgery. IHM was defined as death during the primary hospital stay for
surgical treatment.
Open operations were classified as those that started as open
procedures and those converted from minimally invasive to open
procedures during surgery. Similarly, those classified as RN were
operations that started as RN and PN procedures converted to RN during
surgery.
Minimally invasive methods (MIMs) included pure laparoscopy,
hand-assisted laparoscopy, and robotic-assisted laparoscopy. Ablative
treatments involving cryotherapy or radiofrequency treatment were not
included in the data.
Hospitals performing KC surgery were divided into three groups
according to their mean annual surgical volume: low-volume hospitals
(LVH) performed <20 KC operations per year, intermediate-volume
hospitals (IVH) performed 20–39 KC operations per year, and high-
volume hospitals (HVH) performed40 KC operations per year. The LVH
upper limit was defined according to the 2015 Norwegian regulation
[11], while the HVH lower limit was arbitrarily based on the presumed
volume at the major academic hospitals in Norway.
2.4. Statistical analysis
Standard descriptive statistics were used. Mean values are presented as
mean  standard error of the mean, with median and interquartile range
(IQR) used to indicate variation within groups. Because the proportion of
TDM is low, we applied bootstrapping with 1000 resamples for TDM rates
and associated confidence intervals (CIs). Using this method, we could
simulate TDMrates for 1000 cohorts of 3273 patients (ie, 3 273000patients).
The specific tests used for comparisons between different groups are
indicated. A TDM curve was calculated using the Kaplan-Meier method.
Multiple logistic regression models were established without
preselection of the variables. A p value of <0.05 was considered




In this surgically treated cohort of patients, 69% underwent
RN and 31% PN. In both groups, approximately the same
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proportions underwent open and MIM operations. The
median age was 64 yr and the male/female ratio was 2:1.
Among the tumours, 78% were T1–2Nx–0M0, 14% were T3–
4Nx–0M0, and 8.2% were T1–4Nx–0M1. Supplementary
Table 1 and Table 1 list patient, tumour, and treatment
characteristics for thewhole cohort and the hospital volume
subgroups, respectively.
3.2. TDM
In the present cohort, 29 patients diedwithin 30 d, resulting
in an overall TDM rate of 0.89%. The TDM rate for KC surgery
was 0.73% for localised KC and 2.6% for metastatic disease
(p = 0.007, exact x2 test). Table 2 show the TDM rates for
different TNM categories. TDM was significantly higher for
[(Fig._1)TD$FIG]
Fig. 1 – Flowchart for data extraction from the main database at the Cancer Registry of Norway according to the inclusion and exclusion criteria.
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older age groups, and especially among patients >80 yr,
consistent for all stages (Table 2). Table 3 show the cause of
death for the 29 patients who diedwithin 30 d. Overall TDM
rates were significantly lower for PN and MIM procedures.
According to an analysis of data in the subset (n = 2604),
overall IHM and TDM rates were 0.69% and 0.81%,
respectively.
3.3. Hospital volume
A total of 56 hospitals reported surgical procedures for RCC,
of which 26 performed fewer than four procedures over the
period (40 patients). Consequently, there were 17, nine, and
four hospitals in the LVH, IVH, and HVH groups, with mean
(median, IQR) numbers of procedures of 5.2 /yr (3, 1.3–8.7),
27 /yr (26, 23–30), and 53 /yr (53, 48–58), respectively.
The overall TDM rate was 2.2% for LVH, 0.83% for IVH and
0.39% for HVH. The difference is statistically significant
(Table 2).
Both PN and MIMs were used more extensively in the
HVH group (Tables 1 and 4). Subset analyses revealed that
the LVH group used MIMs for RN to a significantly lesser
degree. In addition, the LVH group had the highest rate of
conversion from MIM to open RN and the highest rate of
subsequent TDM among patients who experienced such
conversion. However, the latter data did not reach statistical
significance (Table 4). Figure 2 shows the mortality within
each volume group during the first 30 d after surgery.
3.4. Multivariate analysis
To identify predictors of TDM following KC surgery, several
factors were entered into a multivariate logistic regression
model (Table 5). Hospital volume, tumour stage, and age all
remained independent TDM predictors. The odds ratio (OR)
for TDMwas 4.98 (95% CI 1.72-14.4) in the LVH compared to
the HVH group (p = 0.003) and 3.35 (95% CI 1.32–8.50) for
patients with distant metastases compared to patients with
pT1–2 disease (p = 0.02). The model was tested and was
stable for OR with regard to these groups.
4. Discussion
This study confirms the predictive ability of older age and
more advanced disease stage with regard to higher TDM.
Both of these are well-established determinants [12].
Table 1 – Comparison of patient and tumour characteristics for the three hospital volume groups
Variable Patients LVH IVH HVH p value







Male 3273 354 (66) 974 (67) 872 (68) 0.4c
Laterality 3264 1.0c
Left 268 (50) 729 (50) 630 (49)
Right 266 (50) 718 (49) 641 (50)
Bilateral 2 (<1) 6 (<1) 4 (<1)







Primary tumour status 2959 <0.001c
pT1aN0M0 226 (46) 639 (49) 610 (52)
pT1b–2N0M0 165 (34) 498 (38) 396 (34)
pT3–4N0M0 99 (20) 164 (13) 162 (14)
Regional lymph node status 3270 0.3c
pNx–0 528 (98) 1416 (97) 1276 (97)
pN+ 11 (2) 39 (3) 39 (3)
Distant metastases 3273 0.5c
No (M0) 499 (93) 1321 (91) 1186 (93)
Yes (M+) 40 (7) 136 (9) 91 (7)
Fuhrman gradea 2628 0.9c
1 40 (9) 103 (9) 83 (8)
2 233 (55) 642 (55) 566 (54)
3 126 (30) 337 (29) 323 (31)
4 24 (6) 81 (7) 70 (7)
Surgical treatment 3273 <0.001c
Radical nephrectomy 407 (76) 1002 (69) 812 (64)
Open 256 (63) 478 (48) 382 (47) <0.001d
Minimally invasive 151 (37) 524 (52) 430 (53)
Partial nephrectomy 119 (22) 430 (30) 449 (35)
Open 91 (76) 204 (47) 208 (46) <0.001d
Minimally invasive 28 (24) 226 (53) 241 (54)
No data available 13 (2) 25 (2) 16 (1)







LVH = low-volume hospitals; IVH = intermediate-volume hospitals; HVH = high-volume hospitals.
Data are presented as mean  standard error of the mean (median, interquartile range) for continuous variables and as n (%) for categorical variables.
a Includes only clear cell and papillary renal cell carcinoma.
b According to t-test between LVH and IVH/HVH combined.
c Exact x2 test for trend over all groups.
d Exact x2 test for trend over all the volume groups within the partial or radical nephrectomy group.
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Although not perfect, age can be seen as a proxy for
comorbid conditions [12]. Furthermore, the threefold to
fourfold higher TDM for M+ disease is well recognised
[2,3,12].
Therefore, the most intriguing finding is identification of
hospital volume as an independent TDM predictor. Older
studies have previously reported this association
[10,15]. Recent studies identified significant correlation
between hospital volume and postoperative complications
[7]. Other studies revealed a definitive correlation between
perioperative mortality and postoperative complications,
but not hospital volume [4,5,16]. The reason for the lack of
Table 2 – TDM rates after kidney cancer surgery for the 6-yr population-based cohort from the Cancer Registry of Norway. To increase the
precision of the estimates, the rates and 95% confidence intervals were obtained via bootstrapping with 1000 resamples
All stages T1-2N0–1M0 T3–4N0–1M0 M+
TDM, %
(95% CI) (n/N)
p value TDM, %
(95% CI) (n/N)
p value TDM, %
(95% CI) (n/N)
p value TDM, %
(95% CI) (n/N)
p valueb
Overall 0.9 (0.6–1.2) (29/3273) 0.007a 0.7 (0.4–1.0) (17/2544) 1.1 (0.2–2.2) (5/455) 2.6 (0.7–4.9) (7/267)
Age 0.001 0.039 0.015 0.028
49 yr 0 (0/439) 0 (0/367) 0 (0/38) 0 (0/34)
50–59 yr 0.6 (0.2–1.2) (4/662) 0.8 (0.2–1.5) (4/530) 0 (0/74) 0 (0/58)
60–69 yr 0.7 (0.3–1.3) (8/1105) 0.6 (0.1–1.2) (5/853) 1.3 (0–3.1) (2/160) 1.1 (0–3.3) (1/92)
70–79 yr 1.1 (0.5–1.9) (9/819) 0.6 (0.2–1.3) (4/626) 0 (0/130) 7.9 (1.6–14.3) (5/63)
80 yr 3.2 (1.3–5.8) (8/248) 2.4 (0.6–4.8) (4/168) 5.7 (0–13.2) (3/53) 5.3 (0–15.8) (1/19)
Gender 0.3 0.4 0.6 0.7
Male 1.0 (0.6–1.4) (22/2200) 0.8 (0.4–1.2) (13/1675) 0.9 (0–2.1) (3/326) 3.1 (1.0–5.6) (6/194)
Female 0.7 (0.2–1.2) (7/1073) 0.5 (0.1–0.9) (4/868) 1.6 (0–3.8) (2/129) 1.4 (0–4.2) (1/73)
Period
(n = 3269)
0.3 0.8 0.4 0.5
1st half 1.1 (0.7–1.6) (18/1641) 0.7 (0.3–1.2) (9/1255) 1.7 (0.4–3.4) (4/233) 3.3 (0.7–6.6) (5/151)
2nd half 0.7 (0.3–1.0) (11/1628) 0.6 (0.2–1.1) (8/1288) 0.5 (0–1.4) (1/222) 1.7 (0–4.3) (2/115)
Procedure 0.03 0.08 1.0 1.0
PN 0.3 (0–0.7) (3/1014) 0.3 (0–0.7) (3/983) 0 (0/22) 0 (0/8)
RN 1.1 (0.7–1.6) (26/2259) 0.9 (0.4–1.4) (14/1561) 1.2 (0.2–2.1) (5/433) 2.7 (1.2–5.0) (7/259)
Technique
(n = 3219)
0.002 0.057 0.7 0.2
Open 1.3 (0.8–1.9) (21/1619) 0.9 (0.4–1.5) (10/1113) 1.3 (0.3–2.7) (4/300) 3.4 (1.0–5.9) (7/205)
MI 0.3 (0.1–0.6) (5/1600) 0.3 (0.1–0.6) (4/1393) 0.7 (0–2.1) (1/146) 0 (0/58)
Hospital volume 0.001 0.004 0.3 0.8
<20 /yr 2.2 (1.1–3.5) (12/539) 1.8 (0.5–3.3) (7/392) 2.9 (0–6.7) (3/104) 5.0 (0–12.5) (2/40)
20–39 /yr 0.8 (0.3–1.3) (12/1457) 0.7 (0.3–1.2) (8/1140) 0.6 (0–1.7) (1/178) 2.2 (0–5.1) (3/136)
40 /yr 0.4 (0.1–0.7) (5/1277) 0.2 (0–0.5) (2/1012) 0,6 (0–1.7) (1/173) 2.2 (0–5.5) (2/91)
TDM = 30-d mortality; PN = partial nephrectomy; RN = radical nephrectomy; MI = minimally invasive; CI = confidence interval.
Unless otherwise indicated n = 3273; data for stage were missing for seven patients.
a p value for x2 test across strata.
b x2 test for comparison of 30-d mortality proportions.
Table 3 – Cause of death for the 29 patients who died within 30 d after kidney cancer surgery
Cause of death n Procedure-related deaths Known relevant comorbid conditions
Gastrointestinal conditions
Complications to GI haemorrhage 1
Complications to intestinal perforation 2 2 (intestinal injuries)
Complications to intestinal necrosis 2 2 (intestinal injuries)
Cardiovascular conditions
Acute myocardial infarction 3
Sudden cardiac arrest 2 2 (substantial heart disease)
Pulmonary embolism 2 1 (other cancer)
Acute subarachnoid haemorrhage 1
Infectious conditions




Renal failure 2 1 (substantial heart disease)
Multiple organ failure 4 1 (haemorrhage)
Renal cell carcinoma
Metastatic kidney cancer 3
Kidney cancer 1
Total 29 5 5
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correlation between hospital volume and perioperative
mortality in contemporary studies is probablymultifaceted.
Low overall perioperative mortality, a lack of valid and
accepted definitions of LVH and HVH, and variable data
quality in different databases are all probably contributing
factors that need to be discussed.
The overall TDM rate of 0.89% is in line with contempo-
rary data for perioperative mortality (0.7–1.4%) [4–7] but is
lower than reports from 15–20 yr ago (2–4%) [10,17–19]. As
mortality rates decrease, demands for larger volumes
increase, and thus the possibility of timely surveillance of
changes in perioperative mortality is impeded [20]. The fact
that most authors use IHM instead of TDM further
complicates this [4–7,16]. As demonstrated in the present
study, the two rates are not necessarily alike, and IHM is
often lower (IHM 0.69%, TDM 0.81%). The most obvious
objection to the use of IHM is that it is highly dependent on
local/regional/national routines for length of stay and
discharge, including the handling of patients dying from
a terminal disease [21,22]. It is documented that a
considerable proportion of perioperative deaths occur after
discharge, but within 30 d [23]. For KC surgery, it will be
important to look for an anticipated increase in this post-
discharge proportion of perioperative deaths as the shorter
length of stay associated with MIMs becomes more
widespread.
Second, LVH andHVH definitions are several and diverse.
The definition range in terms of KC surgeries is 5–25 yr for
LVH and 16–70 /yr for HVH [4,5,7,24]. The issue is
complicated by the fact that some authors used separate
cutoffs for RN and PN in the same study [16], while others
used caseload per surgeon as a stratification tool [2]. The
reasons for group allocation in many studies are difficult to
grasp. In some studies, allocation seems to be based on post
hoc analysis, with simple splitting into parameter tertiles,
though the basis is often not disclosed. In the present study,
LVH was predefined by a new regulation issued by the
Norwegian health authorities. The evidential basis for the
new regulations might be questioned, and our hypothesis
was that no difference would be found. Nevertheless, the
hypothesis was disproved, and in our opinion the data
presented indicate that the higher TDM in the LVH group
should not be disregarded.
Assessment of volume for KC surgery is further
complicated by major changes in treatment introduced
Table 4 – Use of minimally invasive (MI) radical nephrectomy (RN) and conversions to open procedures by hospital volume groups
Variable All hospitals LVH IVH HVH p value
Surgical procedures 2473 407 1108 958
RN procedures 1674 (68) 314 (77) 763 (68) 597 (62) <0.001a









RN started as MI procedure 914 (55) 141 (45) 423 (56) 350 (59) <0.001a
Conversions from MI to open RN 62 (7) 14 (10) 22 (5) 26 (7) 0.2a









TDM among patients with converted procedure 3 (5) 2 (14.3) 1 (4.5) 0 (0) 0.13a
LVH = low-volume hospitals; IVH = intermediate-volume hospitals; HVH = high-volume hospitals; TDM = 30-d mortality.
Data are presented as mean  standard error of the mean (median, interquartile range for continuous variables and as n (%) for categorical variables.
a Exact x2 test between LVH and IVH/HVH combined.
b According to t-test between LVH and IVH/HVH combined.
c Nonparametric Mann-Whitney U-test between LVH and IVH/HVH combined.
Table 5 – Multiple logistic regression analyses to predict 30-d
mortality in patients undergoing surgery for kidney cancer
(n = 3264)
Variable OR (95% CI) p value
Age (continuous in yr) 1.10 (1.05–1.15) <0.001
Gender (male vs female) 2.00 (0.84–4.79) 0.12
Type of nephrectomy (RN vs PN) 2.05 (0.59–7.19) 0.3
pT stage 0.03
T1–2 1.00 (reference)
T3–4 0.99 (0.35–2.78) 1.0
M+ 3.35 (1.32–8.50) 0.01
Hospital volume 0.006
40 /yr 1.00 (reference)
20–39 /yr 1.87 (0.65–5.35) 0.2
<20 /yr 4.98 (1.72–14.4) 0.003
OR = odds ratio; CI = confidence interval; RN = radical nephrectomy;
PN = partial nephrectomy.
[(Fig._2)TD$FIG]
Fig. 2 – Kaplan-Meier plot of cumulative mortality in the different
hospital volume groups during the 30-d period following surgery. Red,
low-volume hospitals (539 patients at risk initially and 527 still at risk
after 30 d), yellow, intermediate-volume hospitals (1457 patients at risk
initially and 1445 still at risk after 30 d); green, high-volume hospitals
(1277 patients at risk initially and 1272 still at risk after 30 d).
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during the last few decades. Open RN used to be the
treatment of choice for all KCs, but choices must be made
today between RN and PN, and between open surgery and
one of several MIMs. Most other studies report lower PN
rates than in our case (5–18% vs 31%), which is probably a
reflection of older data [4,5,7,12,15], when more active use
of PN as advocated by modern guidelines did not apply.
Since 2007, the Norwegian national RCC guidelines have
recommended that all T1a tumours should be assessed for
potential PN. Our study shows that Norwegian LVHs use PN
andMIMs to a lesser extent than IVHs and HVHs. This could
be an indication that<20 KC surgeries per year is below the
threshold for the introduction and routine use of more
advanced surgical procedures such as minimally invasive
PN. This assumption is further supported by the findings
that minimally invasive RN conversion was more frequent
in LVHs and that LVH conversions were for smaller tumours
with poorer TDM outcomes.
The recent introduction of observation as a modality for
the management of smaller KC in older and/or comorbid
patientsmay also have contributed to the higher TDM in the
LVH group. Observation and/or active surveillance in an
organised approach was first introduced at larger academic
centres to avoid overtreatment and unnecessary treatment-
related mortality and morbidity [25]. There is a possibility
that LVHs with less experience choose to perform surgery
on poorer surgical candidates in comparison to larger
centres.
Third, current studies on perioperativemortality, such as
ours, are based on different registries or joint databases.
However, some of these databases only include 10–20% of
the actual population [5,12]. Other nationwide databases
rely on self-reporting by surgeons, with under-reporting of
up to 20% [26]. These limitations might increase difficulties
in demonstrating a volume-mortality effect. The present
study is strengthened by the fact that CRN has more and
independent reporting routines. This enhances the com-
pleteness of the registry, which thus improves the outcome
of studies.
Our study is not without limitations. In particular, access
to data on postoperative complications such as Clavien-
Dindo class [27] and Charlson comorbidity scores [28]
would have deepened understanding of the results. For
example, if such data were available, ‘‘failure to rescue’’
rates could have been addressed. The ability to avoid
mortality after major complications is identified as a
mechanism underlying the difference between high- and
low-mortality hospitals [29,30].
Other limitations include a lack of data regarding
possible confounders, such as surgeon experience and
individual case load, and incomplete data sets on accompa-
nying surgical procedures and history of prior surgery.
Furthermore, as the number of deaths in the present study
was low, there is a risk of overfitting in the multivariate
analysis. The results should therefore be interpreted
accordingly.
Finally, because of the limitations of the present registry,
to achieve better understanding and surveillance of the
quality of KC treatments and outcomes, a dedicated kidney
tumor quality registrymodelled on the Swedish KC Registry
[31] is warranted for the Norwegian KC environment.
5. Conclusions
This population-based study, encompassing a consecutive
6-yr cohort, shows that TDM after KC surgery was 0.9%
overall and in line with previous reports. We also
demonstrated that TDM outcome is significantly poorer
for LVH (<20 procedures/yr). The study supports the new
Norwegian health authority regulation dictating that KC
surgery should be discontinued in this group of hospitals.
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Supplementary Table 1 Patient and tumor characteristics for the six-year 
Norwegian cohort of surgically treated kidney cancer patients 
Variables  Mean±SE (median, IQR) or n % 
Age (years) (n=3273) 63.3±0.2 (64.0, 56-72)  
    
Male gender (n=3273) 2200 67.2 
   
Laterality (n=3264)   
 Left 1627 49.8 
 Right 1625 49.8 
 Bilateral 12 0.4 
    
Tumour size (cm) (n=3294) 5.4±0.1(4.5, 2.6-7.0)  
    
Primary tumour status (TNM 2009) (n=3255)   
 pT1a 1486 45.6 
 pT1b 741 22.7 
 pT2a 244 7.5 
 pT2b 147 4.5 
 pT3a 530 16.3 
 pT3b 49 1.5 
 pT3c 9 0.3 
 pT4 49 1.5 
    
Regional lymph node status (n=3270)   
 pNx-0 3181 97.3 
 pN+ 89 2.7 
    
Distant metastases (n=3273)   
 No (M0) 3006 91.8 
 Yes (M+) 267 8.2 
    
Fuhrman gradea (N=2794)    
 1 226 8.1 
 2 1441 51.6 
 3 786 28.1 
 4 175 6.3 
 NDA 166 5.9 
    
Subtype (n=3270)   
 Clear cell RCC 2294 70.2 
 Papillary RCC 500 15.3 
 Chromophobe RCC 201 6.1 
 Multicystic clear cell RCC 82 2.5 
 Other RCC 122 3.7 
 Unclassifiable 71 2.2 
    
Surgical treatment (n=3273)   
 Radical nephrectomy 2259 69.0 
  Open  1116 49.4 
  Minimal invasive  1105 48.9 
  NDA  38 1.7 
 Partial nephrectomy 1014 31.0 
  Open  503 49.6 
  Minimal invasive  495 48.8 
  NDA  16 1.6 
     
Length of stay (days) (n=2604) 6.3±0.1 (5, 4-7)  
a-includes only clear cell and papillary RCC. IQR – inter quartile range, NDA – no data available,  
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